US20220017583A1 - Affinity support and method for trapping substance using the same - Google Patents
Affinity support and method for trapping substance using the same Download PDFInfo
- Publication number
- US20220017583A1 US20220017583A1 US17/197,828 US202117197828A US2022017583A1 US 20220017583 A1 US20220017583 A1 US 20220017583A1 US 202117197828 A US202117197828 A US 202117197828A US 2022017583 A1 US2022017583 A1 US 2022017583A1
- Authority
- US
- United States
- Prior art keywords
- affinity
- amyloid
- substance
- beads
- support
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000126 substance Substances 0.000 title claims abstract description 216
- 238000000034 method Methods 0.000 title claims abstract description 74
- 125000006850 spacer group Chemical group 0.000 claims abstract description 98
- 230000009146 cooperative binding Effects 0.000 claims abstract description 29
- 230000027455 binding Effects 0.000 claims description 100
- 108010090849 Amyloid beta-Peptides Proteins 0.000 claims description 77
- 102000013455 Amyloid beta-Peptides Human genes 0.000 claims description 77
- 108010064539 amyloid beta-protein (1-42) Proteins 0.000 claims description 36
- 239000012634 fragment Substances 0.000 claims description 28
- 108060003951 Immunoglobulin Proteins 0.000 claims description 24
- 102000018358 immunoglobulin Human genes 0.000 claims description 24
- 238000005406 washing Methods 0.000 claims description 15
- 238000004949 mass spectrometry Methods 0.000 claims description 13
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 claims description 7
- 239000007787 solid Substances 0.000 claims description 3
- 229940072221 immunoglobulins Drugs 0.000 claims 3
- 238000010494 dissociation reaction Methods 0.000 abstract description 16
- 230000005593 dissociations Effects 0.000 abstract description 16
- 238000001926 trapping method Methods 0.000 abstract description 3
- 239000011324 bead Substances 0.000 description 158
- 238000001514 detection method Methods 0.000 description 47
- 125000000524 functional group Chemical group 0.000 description 47
- 239000000523 sample Substances 0.000 description 41
- 239000000427 antigen Substances 0.000 description 27
- 108091007433 antigens Proteins 0.000 description 27
- 102000036639 antigens Human genes 0.000 description 27
- 238000001254 matrix assisted laser desorption--ionisation time-of-flight mass spectrum Methods 0.000 description 23
- 239000011159 matrix material Substances 0.000 description 23
- 229920001223 polyethylene glycol Polymers 0.000 description 23
- 239000000243 solution Substances 0.000 description 22
- 108090000765 processed proteins & peptides Proteins 0.000 description 21
- 210000002381 plasma Anatomy 0.000 description 16
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 15
- 102000004196 processed proteins & peptides Human genes 0.000 description 15
- 239000012472 biological sample Substances 0.000 description 14
- 229920001184 polypeptide Polymers 0.000 description 14
- 238000002360 preparation method Methods 0.000 description 14
- 210000004369 blood Anatomy 0.000 description 13
- 239000008280 blood Substances 0.000 description 13
- 238000004587 chromatography analysis Methods 0.000 description 13
- JCLFHZLOKITRCE-UHFFFAOYSA-N 4-pentoxyphenol Chemical compound CCCCCOC1=CC=C(O)C=C1 JCLFHZLOKITRCE-UHFFFAOYSA-N 0.000 description 12
- 229940079593 drug Drugs 0.000 description 12
- 239000003814 drug Substances 0.000 description 12
- 125000005702 oxyalkylene group Chemical group 0.000 description 12
- -1 polyethylene Polymers 0.000 description 12
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 12
- 239000000499 gel Substances 0.000 description 11
- 239000000090 biomarker Substances 0.000 description 10
- 201000010099 disease Diseases 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 239000012535 impurity Substances 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 9
- 150000001875 compounds Chemical class 0.000 description 9
- ABLZXFCXXLZCGV-UHFFFAOYSA-N phosphonic acid group Chemical group P(O)(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 9
- 102000004169 proteins and genes Human genes 0.000 description 9
- 108090000623 proteins and genes Proteins 0.000 description 9
- 229920005989 resin Polymers 0.000 description 9
- 239000011347 resin Substances 0.000 description 9
- 238000011282 treatment Methods 0.000 description 9
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 8
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 8
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- 239000004365 Protease Substances 0.000 description 7
- 101710120037 Toxin CcdB Proteins 0.000 description 7
- 239000000654 additive Substances 0.000 description 7
- 230000000996 additive effect Effects 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 238000001819 mass spectrum Methods 0.000 description 7
- 238000006116 polymerization reaction Methods 0.000 description 7
- 230000009467 reduction Effects 0.000 description 7
- 229920000936 Agarose Polymers 0.000 description 6
- 108090000270 Ficain Proteins 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 150000005215 alkyl ethers Chemical class 0.000 description 6
- 229920002988 biodegradable polymer Polymers 0.000 description 6
- 239000004621 biodegradable polymer Substances 0.000 description 6
- 239000000091 biomarker candidate Substances 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 238000011156 evaluation Methods 0.000 description 6
- POTUGHMKJGOKRI-UHFFFAOYSA-N ficin Chemical compound FI=CI=N POTUGHMKJGOKRI-UHFFFAOYSA-N 0.000 description 6
- 235000019836 ficin Nutrition 0.000 description 6
- 150000004676 glycans Chemical class 0.000 description 6
- 229920006158 high molecular weight polymer Polymers 0.000 description 6
- 238000001114 immunoprecipitation Methods 0.000 description 6
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 6
- 229910021645 metal ion Inorganic materials 0.000 description 6
- 229920001515 polyalkylene glycol Polymers 0.000 description 6
- 229920005862 polyol Polymers 0.000 description 6
- 150000003077 polyols Chemical class 0.000 description 6
- 229920001282 polysaccharide Polymers 0.000 description 6
- 239000005017 polysaccharide Substances 0.000 description 6
- 230000035945 sensitivity Effects 0.000 description 6
- 229920002554 vinyl polymer Polymers 0.000 description 6
- AFVLVVWMAFSXCK-UHFFFAOYSA-N α-cyano-4-hydroxycinnamic acid Chemical compound OC(=O)C(C#N)=CC1=CC=C(O)C=C1 AFVLVVWMAFSXCK-UHFFFAOYSA-N 0.000 description 6
- 229920002307 Dextran Polymers 0.000 description 5
- 239000004372 Polyvinyl alcohol Substances 0.000 description 5
- 241000700605 Viruses Species 0.000 description 5
- 125000000539 amino acid group Chemical group 0.000 description 5
- 230000000975 bioactive effect Effects 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 238000003795 desorption Methods 0.000 description 5
- LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 5
- 239000012530 fluid Substances 0.000 description 5
- 125000003827 glycol group Chemical group 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- MBKDYNNUVRNNRF-UHFFFAOYSA-N medronic acid Chemical compound OP(O)(=O)CP(O)(O)=O MBKDYNNUVRNNRF-UHFFFAOYSA-N 0.000 description 5
- 229920002451 polyvinyl alcohol Polymers 0.000 description 5
- 102000005962 receptors Human genes 0.000 description 5
- 108020003175 receptors Proteins 0.000 description 5
- 238000001179 sorption measurement Methods 0.000 description 5
- 230000009870 specific binding Effects 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 239000013076 target substance Substances 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 4
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 4
- 108010079855 Peptide Aptamers Proteins 0.000 description 4
- 239000004698 Polyethylene Substances 0.000 description 4
- 239000004743 Polypropylene Substances 0.000 description 4
- 239000004793 Polystyrene Substances 0.000 description 4
- 229920002684 Sepharose Polymers 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 230000001588 bifunctional effect Effects 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 210000001124 body fluid Anatomy 0.000 description 4
- 239000010839 body fluid Substances 0.000 description 4
- 125000004432 carbon atom Chemical group C* 0.000 description 4
- 150000004696 coordination complex Chemical class 0.000 description 4
- 238000010828 elution Methods 0.000 description 4
- 230000007717 exclusion Effects 0.000 description 4
- NBVXSUQYWXRMNV-UHFFFAOYSA-N fluoromethane Chemical compound FC NBVXSUQYWXRMNV-UHFFFAOYSA-N 0.000 description 4
- 239000011521 glass Substances 0.000 description 4
- 239000000383 hazardous chemical Substances 0.000 description 4
- 238000003018 immunoassay Methods 0.000 description 4
- 238000003780 insertion Methods 0.000 description 4
- 230000037431 insertion Effects 0.000 description 4
- 238000002955 isolation Methods 0.000 description 4
- 239000003446 ligand Substances 0.000 description 4
- 229910052751 metal Inorganic materials 0.000 description 4
- 239000002184 metal Substances 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 108091008104 nucleic acid aptamers Proteins 0.000 description 4
- 229920002401 polyacrylamide Polymers 0.000 description 4
- 229920000058 polyacrylate Polymers 0.000 description 4
- 229920002239 polyacrylonitrile Polymers 0.000 description 4
- 229920000728 polyester Polymers 0.000 description 4
- 229920000573 polyethylene Polymers 0.000 description 4
- 229920001155 polypropylene Polymers 0.000 description 4
- 229920002223 polystyrene Polymers 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 239000000741 silica gel Substances 0.000 description 4
- 229910002027 silica gel Inorganic materials 0.000 description 4
- 238000001542 size-exclusion chromatography Methods 0.000 description 4
- 208000014644 Brain disease Diseases 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 239000003463 adsorbent Substances 0.000 description 3
- 125000003277 amino group Chemical group 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000000354 decomposition reaction Methods 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 230000007613 environmental effect Effects 0.000 description 3
- 239000003256 environmental substance Substances 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 125000004185 ester group Chemical group 0.000 description 3
- 208000030533 eye disease Diseases 0.000 description 3
- 208000019622 heart disease Diseases 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 208000026278 immune system disease Diseases 0.000 description 3
- 150000002500 ions Chemical class 0.000 description 3
- 208000017169 kidney disease Diseases 0.000 description 3
- 208000019423 liver disease Diseases 0.000 description 3
- 125000005439 maleimidyl group Chemical group C1(C=CC(N1*)=O)=O 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 229920000136 polysorbate Polymers 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 239000011535 reaction buffer Substances 0.000 description 3
- 239000002002 slurry Substances 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- 238000012916 structural analysis Methods 0.000 description 3
- 239000011534 wash buffer Substances 0.000 description 3
- WXTMDXOMEHJXQO-UHFFFAOYSA-N 2,5-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC(O)=CC=C1O WXTMDXOMEHJXQO-UHFFFAOYSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 102000001301 EGF receptor Human genes 0.000 description 2
- 108060006698 EGF receptor Proteins 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 229920002683 Glycosaminoglycan Polymers 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 2
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 2
- 239000007836 KH2PO4 Substances 0.000 description 2
- 102000057297 Pepsin A Human genes 0.000 description 2
- 108090000284 Pepsin A Proteins 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 2
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 description 2
- 108010034265 Vascular Endothelial Growth Factor Receptors Proteins 0.000 description 2
- PMZXXNPJQYDFJX-UHFFFAOYSA-N acetonitrile;2,2,2-trifluoroacetic acid Chemical compound CC#N.OC(=O)C(F)(F)F PMZXXNPJQYDFJX-UHFFFAOYSA-N 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 210000000601 blood cell Anatomy 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- UFULAYFCSOUIOV-UHFFFAOYSA-N cysteamine Chemical compound NCCS UFULAYFCSOUIOV-UHFFFAOYSA-N 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 239000000539 dimer Substances 0.000 description 2
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 2
- 229910000397 disodium phosphate Inorganic materials 0.000 description 2
- 238000013399 early diagnosis Methods 0.000 description 2
- 125000003700 epoxy group Chemical group 0.000 description 2
- 238000013467 fragmentation Methods 0.000 description 2
- 238000006062 fragmentation reaction Methods 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 229960003151 mercaptamine Drugs 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 125000004430 oxygen atom Chemical group O* 0.000 description 2
- 229940111202 pepsin Drugs 0.000 description 2
- 229920000747 poly(lactic acid) Polymers 0.000 description 2
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 238000003118 sandwich ELISA Methods 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- PCMORTLOPMLEFB-ONEGZZNKSA-N sinapic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC(OC)=C1O PCMORTLOPMLEFB-ONEGZZNKSA-N 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 238000005507 spraying Methods 0.000 description 2
- 125000003396 thiol group Chemical group [H]S* 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- DNIAPMSPPWPWGF-VKHMYHEASA-N (+)-propylene glycol Chemical compound C[C@H](O)CO DNIAPMSPPWPWGF-VKHMYHEASA-N 0.000 description 1
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 1
- GQLPWHMYJOSZCR-UHFFFAOYSA-N (diphosphonoamino)phosphonic acid Chemical compound OP(O)(=O)N(P(O)(O)=O)P(O)(O)=O GQLPWHMYJOSZCR-UHFFFAOYSA-N 0.000 description 1
- YPFDHNVEDLHUCE-UHFFFAOYSA-N 1,3-propanediol Substances OCCCO YPFDHNVEDLHUCE-UHFFFAOYSA-N 0.000 description 1
- PYVHLZLQVWXBDZ-UHFFFAOYSA-N 1-[6-(2,5-dioxopyrrol-1-yl)hexyl]pyrrole-2,5-dione Chemical compound O=C1C=CC(=O)N1CCCCCCN1C(=O)C=CC1=O PYVHLZLQVWXBDZ-UHFFFAOYSA-N 0.000 description 1
- HGUFODBRKLSHSI-UHFFFAOYSA-N 2,3,7,8-tetrachloro-dibenzo-p-dioxin Chemical compound O1C2=CC(Cl)=C(Cl)C=C2OC2=C1C=C(Cl)C(Cl)=C2 HGUFODBRKLSHSI-UHFFFAOYSA-N 0.000 description 1
- GVJXGCIPWAVXJP-UHFFFAOYSA-N 2,5-dioxo-1-oxoniopyrrolidine-3-sulfonate Chemical compound ON1C(=O)CC(S(O)(=O)=O)C1=O GVJXGCIPWAVXJP-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- XYJLPCAKKYOLGU-UHFFFAOYSA-N 2-phosphonoethylphosphonic acid Chemical compound OP(O)(=O)CCP(O)(O)=O XYJLPCAKKYOLGU-UHFFFAOYSA-N 0.000 description 1
- SVNCRRZKBNSMIV-UHFFFAOYSA-N 3-Aminoquinoline Chemical compound C1=CC=CC2=CC(N)=CN=C21 SVNCRRZKBNSMIV-UHFFFAOYSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 108091023037 Aptamer Proteins 0.000 description 1
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- DBVJJBKOTRCVKF-UHFFFAOYSA-N Etidronic acid Chemical compound OP(=O)(O)C(O)(C)P(O)(O)=O DBVJJBKOTRCVKF-UHFFFAOYSA-N 0.000 description 1
- 238000004252 FT/ICR mass spectrometry Methods 0.000 description 1
- 102000002068 Glycopeptides Human genes 0.000 description 1
- 108010015899 Glycopeptides Proteins 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical group ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 102000003982 Parathyroid hormone Human genes 0.000 description 1
- 108090000445 Parathyroid hormone Proteins 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091093037 Peptide nucleic acid Proteins 0.000 description 1
- QLZHNIAADXEJJP-UHFFFAOYSA-N Phenylphosphonic acid Chemical compound OP(O)(=O)C1=CC=CC=C1 QLZHNIAADXEJJP-UHFFFAOYSA-N 0.000 description 1
- GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- YRZBVIGIGZTWGT-UHFFFAOYSA-N [2-(diphosphonoamino)ethyl-phosphonoamino]phosphonic acid Chemical compound OP(O)(=O)N(P(O)(O)=O)CCN(P(O)(O)=O)P(O)(O)=O YRZBVIGIGZTWGT-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 125000003172 aldehyde group Chemical group 0.000 description 1
- HAXFWIACAGNFHA-UHFFFAOYSA-N aldrithiol Chemical group C=1C=CC=NC=1SSC1=CC=CC=N1 HAXFWIACAGNFHA-UHFFFAOYSA-N 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 229940127090 anticoagulant agent Drugs 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 239000003114 blood coagulation factor Substances 0.000 description 1
- 229940019700 blood coagulation factors Drugs 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- KOPOQZFJUQMUML-UHFFFAOYSA-N chlorosilane Chemical group Cl[SiH3] KOPOQZFJUQMUML-UHFFFAOYSA-N 0.000 description 1
- 229960004106 citric acid Drugs 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- AFOSIXZFDONLBT-UHFFFAOYSA-N divinyl sulfone Chemical group C=CS(=O)(=O)C=C AFOSIXZFDONLBT-UHFFFAOYSA-N 0.000 description 1
- 229960001484 edetic acid Drugs 0.000 description 1
- 238000000572 ellipsometry Methods 0.000 description 1
- 238000001952 enzyme assay Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- GOFLNFPIFZZLIP-UHFFFAOYSA-N ethanol;2,2,2-trifluoroacetic acid Chemical compound CCO.OC(=O)C(F)(F)F GOFLNFPIFZZLIP-UHFFFAOYSA-N 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 238000005040 ion trap Methods 0.000 description 1
- 125000001261 isocyanato group Chemical group *N=C=O 0.000 description 1
- 125000001810 isothiocyanato group Chemical group *N=C=S 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- UHNSRFWQBVXBSK-UHFFFAOYSA-N methanol;2,2,2-trifluoroacetic acid Chemical compound OC.OC(=O)C(F)(F)F UHNSRFWQBVXBSK-UHFFFAOYSA-N 0.000 description 1
- 238000004452 microanalysis Methods 0.000 description 1
- 238000002493 microarray Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- DNIAPMSPPWPWGF-UHFFFAOYSA-N monopropylene glycol Natural products CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 1
- LYGCMUNBGIOQAB-UHFFFAOYSA-N naphthalen-1-ylmethylphosphonic acid Chemical compound C1=CC=C2C(CP(O)(=O)O)=CC=CC2=C1 LYGCMUNBGIOQAB-UHFFFAOYSA-N 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 239000000199 parathyroid hormone Substances 0.000 description 1
- 229960001319 parathyroid hormone Drugs 0.000 description 1
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 1
- 150000003071 polychlorinated biphenyls Chemical group 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229920000166 polytrimethylene carbonate Polymers 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 238000007420 radioactive assay Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000012764 semi-quantitative analysis Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- PCMORTLOPMLEFB-UHFFFAOYSA-N sinapinic acid Natural products COC1=CC(C=CC(O)=O)=CC(OC)=C1O PCMORTLOPMLEFB-UHFFFAOYSA-N 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- RPENMORRBUTCPR-UHFFFAOYSA-M sodium;1-hydroxy-2,5-dioxopyrrolidine-3-sulfonate Chemical compound [Na+].ON1C(=O)CC(S([O-])(=O)=O)C1=O RPENMORRBUTCPR-UHFFFAOYSA-M 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000012421 spiking Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000013638 trimer Substances 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
Images
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
- B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 - B01D15/36
- B01D15/3804—Affinity chromatography
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
- B01D15/34—Size selective separation, e.g. size exclusion chromatography, gel filtration, permeation
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
- B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 - B01D15/36
- B01D15/3804—Affinity chromatography
- B01D15/3809—Affinity chromatography of the antigen-antibody type, e.g. protein A, G, L chromatography
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
- B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 - B01D15/36
- B01D15/3847—Multimodal interactions
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/281—Sorbents specially adapted for preparative, analytical or investigative chromatography
- B01J20/286—Phases chemically bonded to a substrate, e.g. to silica or to polymers
- B01J20/289—Phases chemically bonded to a substrate, e.g. to silica or to polymers bonded via a spacer
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/30—Processes for preparing, regenerating, or reactivating
- B01J20/32—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating
- B01J20/3202—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating characterised by the carrier, support or substrate used for impregnation or coating
- B01J20/3204—Inorganic carriers, supports or substrates
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/30—Processes for preparing, regenerating, or reactivating
- B01J20/32—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating
- B01J20/3202—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating characterised by the carrier, support or substrate used for impregnation or coating
- B01J20/3206—Organic carriers, supports or substrates
- B01J20/3208—Polymeric carriers, supports or substrates
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/30—Processes for preparing, regenerating, or reactivating
- B01J20/32—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating
- B01J20/3214—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating characterised by the method for obtaining this coating or impregnating
- B01J20/3217—Resulting in a chemical bond between the coating or impregnating layer and the carrier, support or substrate, e.g. a covalent bond
- B01J20/3219—Resulting in a chemical bond between the coating or impregnating layer and the carrier, support or substrate, e.g. a covalent bond involving a particular spacer or linking group, e.g. for attaching an active group
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/30—Processes for preparing, regenerating, or reactivating
- B01J20/32—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating
- B01J20/3231—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating characterised by the coating or impregnating layer
- B01J20/3242—Layers with a functional group, e.g. an affinity material, a ligand, a reactant or a complexing group
- B01J20/3268—Macromolecular compounds
- B01J20/3272—Polymers obtained by reactions otherwise than involving only carbon to carbon unsaturated bonds
- B01J20/3274—Proteins, nucleic acids, polysaccharides, antibodies or antigens
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54353—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals with ligand attached to the carrier via a chemical coupling agent
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- H—ELECTRICITY
- H01—ELECTRIC ELEMENTS
- H01J—ELECTRIC DISCHARGE TUBES OR DISCHARGE LAMPS
- H01J49/00—Particle spectrometers or separator tubes
- H01J49/0027—Methods for using particle spectrometers
-
- H—ELECTRICITY
- H01—ELECTRIC ELEMENTS
- H01J—ELECTRIC DISCHARGE TUBES OR DISCHARGE LAMPS
- H01J49/00—Particle spectrometers or separator tubes
- H01J49/02—Details
- H01J49/10—Ion sources; Ion guns
- H01J49/16—Ion sources; Ion guns using surface ionisation, e.g. field-, thermionic- or photo-emission
- H01J49/161—Ion sources; Ion guns using surface ionisation, e.g. field-, thermionic- or photo-emission using photoionisation, e.g. by laser
- H01J49/164—Laser desorption/ionisation, e.g. matrix-assisted laser desorption/ionisation [MALDI]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4703—Regulators; Modulating activity
Definitions
- the present invention relates to high-sensitivity measurement and/or structural analysis of molecules contained in a biological sample or the like.
- the present invention relates to initial diagnosis of diseases, follow-up of diseases, and/or a technique for evaluating chemotherapeutic sensitivity.
- a specific polypeptide peptide or protein
- a biological sample such as a cell extract, a tissue extract, or a body fluid (e.g., blood, urine, or spinal fluid)
- a method using chromatography and a method using molecules having the ability of specific binding, that is, affinity molecules are used.
- Examples of the method using chromatography include a method using reverse phase chromatography and a method using ion-exchange chromatography.
- Examples of the method using affinity molecules include a method using an affinity support.
- Patent Document 1 JP 7-268000 A discloses an immune adsorbent composed of a carrier and an antibody bound to the carrier, and describes that the immune adsorbent can be prepared using a polyclonal antibody or a monoclonal antibody as the antibody, and using a crosslinking agent such as N,N′-hexamethylenebismaleimide in order to bind the antibody to the carrier.
- a crosslinking agent such as N,N′-hexamethylenebismaleimide
- Non-Patent Document 1 (Analytical Biochemistry 1999 Nov. 15; 275(2): 262-5) discloses semiquantitative analysis of amyloid ⁇ peptides using a combination of immunoprecipitation and MALDI mass spectrometry.
- Non-Patent Document 2 (Proceedings of the Japan Academy, Ser. B, Physical and Biological Sciences 2011; 87(9): 603-16) describes a preparation of a flexible antibody-like molecule composed of an antibody Fc fragment, a hinge region bound to the antibody Fc fragment and having polyethylene glycol, and amyloid ⁇ bound to the hinge region.
- Non-Patent Document 2 describes that a molecule having two amyloid ⁇ peptides (i.e., a two-handed molecule) and a molecule having one amyloid ⁇ peptide (i.e., a one-handed molecule) are obtained by the preparation. Further, Non-Patent Document 2 describes that when anti-amyloid ⁇ antibody is an objective to be trapped, binding between the two-handed molecule and anti-amyloid ⁇ antibody achieves a lower dissociation constant K D than binding between the one-handed molecule and anti-amyloid ⁇ antibody.
- Patent Document 2 (WO2005/037881) describes that a carrier prepared by fixing a ligand to a resin obtained by polymerization of a monomer component having a hydrophilic spacer inserted therein is used to reduce non-specific adsorption to the carrier.
- the method using chromatography performs separation and concentration of a target polypeptide in a stepwise fashion using several kinds of carriers, and therefore inevitably requires a large amount of biological sample.
- the method using affinity molecules can isolate a target polypeptide in a single treatment due to specific binding achieved by the affinity between molecules, and therefore requires only a minute amount of biological sample. From such a viewpoint, the method using affinity molecules makes up for the shortcomings of the method using chromatography in terms of the amount of a biological sample required. Further, the method using affinity molecules requires less time and is versatile.
- the collection rate of a target molecule e.g., a polypeptide
- the amount of incorporated impurities depend on the properties of an affinity carrier (e.g., an immune adsorbent or protein A/G beads).
- an affinity carrier e.g., an immune adsorbent or protein A/G beads.
- the affinity carrier is one using an antibody
- the efficiency of trapping a target molecule or the amount of non-specifically adsorbed impurities depends on the titer of the antibody.
- Such limitations inevitably imposed by the properties of the affinity carrier lead to limitations of analytical sensitivity or specificity in mass spectrograph or SDS-PAGE of the target molecule collected by the affinity carrier. Such a problem often results in difficulty in analysis particularly in researches on minute amounts of biomolecules.
- Patent Document 2 The method disclosed in Patent Document 2 is limited to applications using ligands and merely reduces non-specific adsorption, and therefore cannot specifically trap specific target molecules.
- PEG inserted into the hinge region of an antibody provides an appropriate interval between two amyloid ⁇ peptides (1-15), which makes it possible to simultaneously bind the two amyloid ⁇ peptides (1-15) to two F(ab) regions of 6E10, respectively.
- cooperative binding by binding of one two-handed molecule to one molecule via both two hands of said two-handed molecule (in the present specification, referred to as “cooperative binding”), a binding (with a 100 to 100,000 times lower dissociation constant K D ) that is less likely to cause dissociation than binding of one one-handed molecule to one molecule via only one hand of said one-handed molecule is achieved.
- a binding mode in which one one-handed molecule binds to one molecule via only one hand of said one-handed molecule is the same as that in which a normal antibody binds to an objective to be trapped by the antibody. From such a viewpoint, binding with a low dissociation constant K D , that is, cooperative binding achieved by the method disclosed in Non-Patent Document 2 is expected to make up for the shortcomings of the methods disclosed in Patent Document 1 and Non-Patent Document 1 in terms of the titer of antibody.
- Non-Patent Document 2 does not suggest the possibility of achieving cooperative binding between the antibody-like molecule and various molecules other than antibodies, especially polypeptides, which are different in size and shape and may be generally objectives to be trapped by affinity carriers.
- a mass spectrometer is a powerful tool for structural analysis of biomolecules.
- biomolecules as an objective to be analyzed contained in the biological sample need to be concentrated.
- a mass spectrometer has a limitation in its detectable level, and therefore an objective to be analyzed in a sample subjected to mass spectrometry needs to be concentrated to a detectable level.
- impurities other than the objective to be analyzed need to be removed. This is because impurities contained in a sample subjected to mass spectrometry cause an increase in the background of data or ion suppression that interferes with the detection of the objective to be analyzed.
- the present invention includes the following inventions.
- An affinity support comprising a support, a spacer bound to the support and an affinity substance bound to the spacer, wherein two to five kinds of the affinity substance bound to the spacer exist in a mixed state.
- affinity support according to the above, wherein the affinity substance is an amino acid or a peptide having 2 to 50 amino acid residues.
- affinity support according to any of the above (1) to (7), wherein the affinity substance is selected from the group consisting of an immunoglobulin, an immunoglobulin F(ab′) fragment, an immunoglobulin F(ab) fragment, an immunoglobulin Fv fragment, a nucleic acid aptamer, a peptide aptamer, a receptor protein, and a bioactive substance.
- a method of trapping a substance comprising the step of contacting an objective to be trapped with an affinity support comprising a support, a spacer bound to the support and an affinity substance bound to the spacer, so as to bind the objective to be trapped to the affinity substance, wherein each one of the objective to be trapped has a plural of affinity sites and the affinity substance binds to at least two of the affinity sites simultaneously.
- a binding mode in which simultaneous binding of at least two affinity substances to at least two affinity sites (i.e., sites to which affinity substances specifically bind) present in a substance to be trapped is achieved is referred to as cooperative binding.
- cooperative binding it is not required that simultaneous binding to the at least two affinity sites should be always achieved, and for example, there may be a moment when only one of the at least two affinity sites is bound to the affinity substance. That is, cooperative binding is in a state where any one of two or more affinity sites of a substance to be trapped substantially always is bound to an affinity substance so that complete dissociation between the substance to be trapped and the affinity substance is less likely to occur.
- the support is made of a material selected from the group consisting of an agarose, a sepharose, a dextran, a silica gel, a polyacrylamide, a polystyrene, a polyethylene, a polypropylene, a polyester, a polyacrylonitrile, a (meth)acrylic polymer, a fluorocarbon resin, a metal complex resin, a glass, a metal, and a magnetic substance.
- the affinity substance is selected from the group consisting of an immunoglobulin, an immunoglobulin F(ab′) fragment, an immunoglobulin F(ab) fragment, an immunoglobulin Fv fragment, a nucleic acid aptamer, a peptide aptamer, a receptor protein, and a bioactive substance.
- each one of the objective to be trapped is one multimer or one aggregate which comprises a plural of molecules, and each of the plural of the affinity sites exists on each of the plural of the molecules.
- a method of micro mass spectrometry comprising the steps of:
- the present invention provides an affinity support comprising a support, a spacer bound to the support and an affinity substance bound to the spacer, wherein two to five kinds of the affinity substance bound to the spacer exist in a mixed state.
- the length of the spacer is 1 to 100 nm.
- the spacer comprises an oxyalkylene group.
- the spacer is selected from the group consisting of a polyalkylene glycol, a polyoxyalkylated polyol, a polyvinyl alcohol, a polyvinyl alkyl ether, a polysaccharide, a biodegradable polymer, and a lipopolymer.
- the spacer is branched, the support is bound to a main chain of the spacer, and the affinity substance is bound to a branched chain of the spacer.
- an interval between binding positions on the support of the spacers bound to the affinity substances is 1 to 50 angstrom ( ⁇ ).
- the support is made of a material selected from the group consisting of an agarose, a sepharose, a dextran, a silica gel, a polyacrylamide, a polystyrene, a polyethylene, a polypropylene, a polyester, a polyacrylonitrile, a (meth)acrylic polymer, a fluorocarbon resin, a metal complex resin, a glass, a metal, and a magnetic substance.
- a material selected from the group consisting of an agarose, a sepharose, a dextran, a silica gel, a polyacrylamide, a polystyrene, a polyethylene, a polypropylene, a polyester, a polyacrylonitrile, a (meth)acrylic polymer, a fluorocarbon resin, a metal complex resin, a glass, a metal, and a magnetic substance.
- the affinity substance is selected from the group consisting of an immunoglobulin, an immunoglobulin F(ab′) fragment, an immunoglobulin F(ab) fragment, an immunoglobulin Fv fragment, a nucleic acid aptamer, a peptide aptamer, a receptor protein, and a bioactive substance.
- the present invention provides a method of trapping a substance comprising the step of contacting an objective to be trapped with an affinity support comprising a support, a spacer bound to the support and an affinity substance bound to the spacer, so as to bind the objective to be trapped to the affinity substance, wherein each one of the objective to be trapped has a plural of affinity sites and the affinity substance binds to at least two of the affinity sites simultaneously.
- one kind of the affinity substance bound to the spacer exists on the affinity support.
- two to five kinds of the affinity substance bound to the spacer exist in the mixed state on the affinity support.
- the spacer comprises an oxyalkylene group.
- the spacer is selected from the group consisting of a polyalkylene glycol, a polyoxyalkylated polyol, a polyvinyl alcohol, a polyvinyl alkyl ether, a polysaccharide, a biodegradable polymer, and a lipopolymer.
- each one of the objective to be trapped is one multimer or one aggregate which comprises a plural of molecules, and each of the plural of the affinity sites exists on each of the plural of the molecules.
- each one of the objective to be trapped is one molecule.
- the objective to be trapped is a biological substance or a non-biological substance.
- the biological substance is selected from the group consisting of a biomarker, a biomarker candidate molecule, and a fragment generated from a biomarker or a biomarker candidate molecule by splicing.
- the biomarker is related to a disease selected from the group consisting of cancer, brain disease, heart disease, immune disease, hepatic disease, renal disease, and eye disease.
- the biological substance is a virus or a bacterium.
- the non-biological substance is an environmentally hazardous substance.
- an affinity support capable of trapping a substance by cooperative binding that is less likely to cause dissociation even when the substance is a molecule other than an antibody, and a trapping method using the same.
- the affinity support according to the present invention achieves a 100 to 100,000 times lower dissociation constant K D than a conventional affinity support. Therefore, the use of the affinity support according to the present invention makes it possible to more efficiently isolate and concentrate a target molecule in a sample (i.e., to bind a target molecule to the affinity support to isolate them from a sample in a concentrated state) as compared to the use of the conventional affinity support. For example, a trapping rate about 5.6 to 8.5 times (molar basis) higher than that of a conventional immunoprecipitation method is achieved, and the sensitivity of analysis of a trapped substance by a mass spectrometer is improved 10-fold. Further, the low dissociation constant K D makes it possible to expand washing conditions and/or reduce non-specific adsorption.
- FIG. 1 is a schematic diagram showing a method for producing F(ab′)-PEG beads that is one embodiment of an affinity support according to the present invention.
- FIG. 2 is a size exclusion chromatogram of a Ficin digest of 6E10.
- FIG. 3A shows the image of a gel obtained by reducing SDS-PAGE chromatography of the 6E10 digest
- FIG. 3B shows the image of a gel obtained by non-reducing SDS-PAGE chromatography of the 6E10 digest.
- FIGS. 4A and 4B are size exclusion chromatograms of a 6E10 F(ab′) 2 fraction before ( FIG. 4A ) and after ( FIG. 4B ) reduction treatment to determine the generation of 6E10 F(ab′) fragments by the reduction treatment.
- FIG. 5 shows the image of a gel obtained by SDS-PAGE chromatography to determine the presence of aggregates of amyloid ⁇ (1-42).
- FIG. 6 is a graph showing the amounts of trapped amyloid ⁇ (1-42) when reaction solutions containing a fixed amount (100 ng) of amyloid ⁇ (1-42) and having different liquid amounts (10, 100, and 1,000 ⁇ L) were subjected to various affinity supports (6E10 F(ab′)-PEG 24 beads, 6E10 F(ab′)-PEG 2 beads, and 6E10 IgG-protein G beads), respectively.
- FIG. 7 shows a comparison of MALDI-TOF MS spectra obtained when different amounts of amyloid ⁇ (1-42) were trapped using various affinity supports (6E10 IgG-protein G beads ( FIG. 7A ), 6E10 F(ab′)-PEG 2 beads ( FIG. 7B ), and 6E10 F(ab′)-PEG 24 beads ( FIG. 7C ) and the MALDI-TOF MS spectrum of pure amyloid ⁇ (1-42) ( FIG. 7D ).
- FIG. 8 is a size exclusion chromatogram of a LysC digest of 4G8;
- FIG. 9A shows the image of a gel obtained by reducing SDS-PAGE chromatography of the 4G8 digest
- FIG. 9B shows the image of a gel obtained by non-reducing SDS-PAGE chromatography of the 4G8 digest.
- FIG. 10 shows a comparison of MALDI-TOF MS spectra obtained when different amounts of amyloid ⁇ (1-28) were trapped using various affinity supports (6E10 IgG-protein G beads ( FIG. 10A ), 4G8 IgG-protein G beads ( FIG. 10B ), 6E10/4G8 IgG-protein G beads ( FIG. 10C ), 6E10 F(ab′)-PEG 24 beads ( FIG. 10D ), 4G8 F(ab′)-PEG 24 beads ( FIG. 10E ), and 6E10/4G8 F(ab′)-PEG 24 beads ( FIG. 10F ) and the MALDI-TOF MS spectrum of pure amyloid ⁇ (1-28) ( FIG. 10G ).
- 6E10 IgG-protein G beads FIG. 10A
- 4G8 IgG-protein G beads FIG. 10B
- 6E10/4G8 IgG-protein G beads FIG. 10C
- 6E10 F(ab′)-PEG 24 beads FIG.
- FIG. 11 shows mass spectra obtained when human plasma in which amyloid ⁇ (1-28) was spiked was subjected to an affinity support (6E10 F(ab′)-PEG 24 beads).
- FIG. 12 shows a comparison of MALDI-TOF MS spectra obtained when different amounts of amyloid ⁇ (1-28) spiked in human plasma were trapped using various affinity supports (6E10 IgG-protein G beads ( FIG. 12A ), 4G8 IgG-protein G beads ( FIG. 12B ), 6E10/4G8 IgG-protein G beads ( FIG. 12C ), 6E10 F(ab′)-PEG 24 beads ( FIG. 12D ), 4G8 F(ab′)-PEG 24 beads ( FIG. 12E ), and 6E10/4G8 F(ab′)-PEG 24 beads ( FIG. 12F ) and the MALDI-TOF MS spectrum of pure amyloid ⁇ (1-28) ( FIG. 12G ).
- 6E10 IgG-protein G beads FIG. 12A
- 4G8 IgG-protein G beads FIG. 12B
- 6E10/4G8 IgG-protein G beads FIG. 12C
- FIG. 13 shows a mass spectrum obtained when 1 pg (307 amol) of amyloid ⁇ (1-28) spiked in human plasma was trapped using an affinity support (6E10/4G8 F(ab′)-PEG 24 beads).
- An affinity support according to the present invention comprises a support, a spacer bound to the support, and an affinity substance bound to the spacer.
- bound includes direct binding and indirect binding.
- the material of the support may be selected from the group consisting of an agarose, a sepharose, a dextran, a silica gel, a polyacrylamide, a polystyrene, a polyethylene, a polypropylene, a polyester, a polyacrylonitrile, a (meth)acrylic polymer, a fluorocarbon resin, a metal complex resin, a glass, a metal, and a magnetic substance.
- the support may have any shape such as a planar shape, a spherical shape, or the like.
- the support may constitute a chip, a bead, or a flow channel wall in a microdevice for use in separation and/or concentration of a target substance.
- one of the ends of the spacer is bound to the support and the other end is bound to the affinity substance.
- the spacer can play a role in keeping an appropriate interval between the support and the affinity substance, and in imparting flexibility, or both of flexibility and extensibility to said spacer itself to achieve cooperative binding.
- the spacer preferably has a chain-like (spacer chain) structure. The presence of the chain-like spacer reduces steric hindrance at the support when an objective to be trapped binds to the affinity substance as compared to when the chain-like spacer is not present. As a result, it is possible to enhance the binding strength between the affinity substance and the objective to be trapped.
- the length of the spacer is, for example, 1 to 100 nm, preferably 1 to 20 nm, more preferably 5 to 10 nm.
- the spacer is too short and therefore reach of said spacer is not enough to simultaneously bind two or more affinity substances to two or more affinity sites of an objective to be trapped so that cooperative binding is less likely to occur.
- the spacer exceeds the above upper limit, the spacer is too long and therefore the degree of freedom of movable range of the affinity substance is contrarily limited so that cooperative binding is less likely to occur.
- the spacer may be, for example, a high molecular weight polymer.
- the high molecular weight polymer used as the spacer in the present invention usually has a chain-like structure.
- the spacer is preferably non-peptidic.
- non-peptidic means having no peptide binding.
- the non-peptidic spacer may contain an oxyalkylene group.
- An oxyalkylene group-containing group is a divalent group, and may be, for example, one having 2 to 6 carbon atoms. More specifically, an oxyalkylene in the oxyalkylene group-containing group is ethylene oxide or propylene oxide.
- the oxyalkylene group-containing group is preferably an organic high molecular weight polymer, that is, a polyoxyalkylene group-containing group.
- the polyoxyalkylene group-containing group is preferably a polyalkylene glycol group obtained by polymerization of an alkylene glycol having 2 to 6 carbon atoms (e.g., polymerization degree: 2 to 40).
- the polyalkylene glycol group may be selected from the group consisting of polyethylene glycol group (obtained by polymerization of ethylene glycol), and polypropylene glycol group (obtained by polymerization of 1,2-propanediol or 1,3-propanediol).
- an ethylene glycol group or a polyethylene glycol group having a polymerization degree of 2 to 40, preferably 12 to 36 may be selected as the oxyalkylene group-containing group.
- the non-peptidic spacer may be, for example, an organic high molecular weight polymer selected from the group consisting of a polyoxyalkylated polyol, a polyvinyl alcohol, a polyvinyl alkyl ether, a polysaccharide, a biodegradable polymer, and a lipopolymer.
- An alkyl group in the polyoxyalkylated polyol or the polyvinyl alkyl ether may have, for example, 1 to 6 carbon atoms, preferably 1 to 3 carbon atoms.
- the polysaccharide include a dextran, a mucopolysaccharide, and a chitin.
- the mucopolysaccharide include hyaluronic acid.
- the biodegradable polymer include PLA (poly(lactic acid)) and PLGA (poly(lactic-glycolic acid)).
- organic high molecular weight polymers may have a polymerization degree of, for example, 2 to 40, preferably 12 to 36.
- the spacer may be a polypeptide.
- polypeptide is used as a generic name for peptides (having, for example, 2 or more and 100 or less amino acid residues) and proteins (having, for example, more than 100 amino acid residues).
- the polypeptide as the spacer may be a ligand having an affinity for a constant region. Examples of such a ligand include protein A and protein G.
- the spacer used in the present invention may be one containing one of the above-mentioned examples or one containing any two or more selected from the above-mentioned examples.
- the spacer may be straight chain or branched chain.
- the support is bound to the end of one of chains, that is, a main chain, and the affinity substance is bound to the end of the other chain, that is, a branched chain.
- the number of branched chains is not particularly limited, and may be, for example, 2 to 10.
- the spacer is branched, the density of the affinity substance on the affinity support can be increased as compared to when the spacer is straight chain.
- the affinity substance may be either a guest substance or a host substance that can generally construct a molecular recognition system and can interact by non-covalent bonding.
- the affinity substance is preferably a host substance.
- interaction in molecular recognition means that the affinity substance recognizes and non-covalently interacts with an affinity site of an objective to be trapped, and may be, for example, specific binding with such an affinity that an association rate constant ka (unit: 1/Ms) of at least 10 3 or 10 4 , for example, 10 3 to 10 5 or 10 4 to 10 5 is achieved.
- the number of specific binding sites per one affinity substance may be one or two or more (e.g., five or less).
- the affinity substance may or may not have a naturally-derived structure.
- the affinity substance examples include amino acids and polypeptides. More specifically, the affinity substance may be an amino acid or a polypeptide having 2 to 50 amino acid residues.
- the affinity substance is one selected from the group consisting of an immunoglobulin and an immunoglobulin fragment.
- the immunoglobulin fragment is not particularly limited as long as it has the ability to bind to antigen, and can be selected from, for example, the group consisting of F(ab′)2, F(ab′), Fab, Fd, Fv, L-chain, and H-chain.
- the immunoglobulin fragment is preferably selected from the group consisting of an immunoglobulin F(ab′) fragment, an immunoglobulin F(ab) fragment, and a Fv fragment which have no Fc region.
- the immunoglobulin include IgG1, IgG2, IgG3, IgG4, and the like.
- the immunoglobulin may be derived from any animal, but is particularly derived from a human.
- affinity substance is one selected from the group consisting of a nucleic acid aptamer, a peptide aptamer, a receptor protein, and a bioactive substance.
- bioactive substance include cytokine, hormones, and neurotransmitters.
- the interval between binding positions on the support of the spacers bound to the affinity substances is not particularly limited, and can be appropriately determined by those skilled in the art so that the affinity substances are preferably present as dense as possible. More specifically, the interval between the affinity substance-binding positions may vary depending on, for example, the size of the affinity substance, but is, for example, 1 to 1,000 angstrom ( ⁇ ), preferably 1 to 100 angstrom, more preferably 1 to 50 angstrom, even more preferably 1.5 to 30 angstrom.
- the above lower limit substantially corresponds to the physical limit of the interval between adjacent affinity substances.
- the affinity substances are sparse and therefore cooperative binding is less likely to occur.
- one kind of the affinity substance bound to the support via the spacer is present on the support (more specifically, in a specific region on the support).
- two or more kinds of the affinity substances bound to the support via the spacer are present on the support (more specifically, in a specific region on the support).
- the number of kinds of the affinity substances used in this embodiment is two or more, but is smaller than, for example, the number of kinds of antibodies constituting a common polyclonal antibody.
- the amounts of two to five kinds of the affinity substances are preferably the same or close to each other. More specifically, two to five kinds of the affinity substances can be used in such a manner that the difference in amount between arbitrary two kinds of the affinity substances selected from the two to five kinds of affinity substances is within 20%, preferably within 10%, more preferably within 5% (molar basis).
- different kinds of the affinity substances are present on the same support in a mixed state.
- the embodiment in which different kinds of the affinity substances are present on the same support in a mixed state is clearly distinguished from an embodiment in which different kinds of the affinity substances are bound in a state where they can be differentiated from each other (e.g., a microarray).
- Treatment may be performed on the specific region on the support depending on the kind of affinity substance bound thereto or the combination of different kinds of the affinity substances bound thereto.
- Two or more regions may be provided on the same support in such a manner that the kind of affinity substance bound thereto or the combination of different kinds of the affinity substances bound thereto varies from region to region. In this case, different treatments can be performed on the different regions on the same support.
- the affinity support according to the present invention can be prepared by binding a support having a binding functional group on surface of said support to an affinity substance having a binding functional group via a spacer substance having both a binding functional group corresponding to the binding functional group of the support and a binding functional group corresponding to the binding functional group of the affinity substance simultaneously (i.e., a bifunctional spacer substance) or successively (i.e., a monofunctional spacer substance).
- the binding functional group of each of the components may be selected from the group consisting of covalent binding functional group, ion binding functional group, and hydrogen binding functional group. Particularly, a covalent binding functional group is preferred.
- a combination of binding functional groups of the components corresponding to each other can be easily determined by those skilled in the art so that binding selected from the group consisting of covalent binding, ion binding, and hydrogen binding, preferably covalent binding can be achieved.
- binding functional group of one of the components is an amino group
- binding functional group of the corresponding other component examples include a carboxyl group, an active ester group (e.g., an N-hydroxysuccinimide (NHS) ester group, and an N-hydroxysulfosuccinimide (Sulfo-NHS) ester group), an epoxy group, an aldehyde group, an isocyanato group, an isothiocyanato group, and the like.
- an active ester group e.g., an N-hydroxysuccinimide (NHS) ester group, and an N-hydroxysulfosuccinimide (Sulfo-NHS) ester group
- an epoxy group e.g., an aldehyde group, an isocyanato group, an isothiocyanato group, and the like.
- binding functional group of one of the components is a thiol group
- binding functional group of the corresponding other component examples include a maleimide group, a pyridyldisulfide group, a vinylsulfone group, a bromoacetyl group, and the like.
- binding functional group of one of the components is a hydroxyl group
- binding functional group of the corresponding other component examples include an epoxy group, a silyl chloride group, and the like.
- the support having a binding functional group on a surface of said support can be prepared by a self-organizing surface method in which molecules having a binding functional group are arranged on the surface of a support; a method in which the surface of a support is coated with a substance having a binding functional group; a method in which a substance having a binding functional group and a functional group that can covalently bind to a support is covalently bound to the surface of the support; or the like.
- the support having a binding functional group on a surface of said support is preferably prepared by the method based on covalent binding.
- an amino group is particularly preferred as the binding functional group of the support.
- the density of the binding functional group on the support is, for example, 0.001 to 0.5 mmol/m 2 , preferably 0.01 to 0.1 mmol/m 2 .
- Each of the binding functional groups of the spacer substance may be one that is naturally present in a biomolecule, one that an organic high molecular weight polymer previously has, or one that is artificially produced by decomposition, synthesis, or modification.
- a method for producing the binding functional group can be easily selected by those skilled in the art.
- the binding functional group of the spacer substance corresponding to the binding functional group of the support and the binding functional group of the spacer substance corresponding to the binding functional group of the affinity substance may be the same or different from each other.
- a particularly preferred example of a combination of the binding functional groups of the spacer substance is a combination of an active ester group and a maleimide group.
- the binding functional group of the affinity substance may be one that is naturally present in a naturally-derived structure or one that is artificially produced by decomposition, synthesis, or modification. That is, the affinity substance having a binding functional group is prepared by a method appropriately selected by those skilled in the art from, for example, isolation from the living body of an organism, decomposition of an isolate from a living body, synthesis by genetic engineering, biochemical synthesis and modification, and organic chemical synthesis and modification. Among the above-mentioned examples of the binding functional group, a thiol group is particularly preferred as the binding functional group of the affinity substance.
- the immunoglobulin fragment can be prepared by digestion using an enzyme (e.g., papain, pepsin, ficin, or the like), and/or by cleavage of disulfide bonds using a reducing agent.
- an enzyme e.g., papain, pepsin, ficin, or the like
- binding between the spacer substance and the affinity substance may be achieved after the support and the spacer substance are bound to each other, or binding between the spacer substance and the support may be achieved after the affinity substance and the spacer substance are bound to each other.
- the spacer substance may be either monofunctional or bifunctional.
- the respective components may be bound to one another by, for example, binding the support having a binding functional group to the monofunctional spacer substance having a binding functional group corresponding to the binding functional group of the support, and then producing a binding functional group of the spacer substance corresponding to a binding functional group of the affinity substance, and then binding the spacer substance to the affinity substance via the produced binding functional group.
- the respective components may be bound to one another simultaneously by using a bifunctional spacer substance as the spacer substance and subjecting the support, the bifunctional spacer substance, and the affinity substance to the same reaction system.
- the respective components are used in such amounts that the affinity substance is bound as dense as possible. More specifically, the spacer substance can be used in an amount 10 to 5,000 times (molar basis) the amount of the binding functional group present in a region on the support where the affinity substance is to be bound, and the affinity substance can be used in an amount 0.1 to 10 times (molar basis) the amount of the binding functional group present in a region on the support where the affinity substance is to be bound.
- the affinity support according to the present invention can be used by subjecting said affinity support to a molecular recognition system selected by those skilled in the art depending on the affinity substance bound thereto. More specifically, a sample containing a substance to be trapped is brought into contact with the affinity support to bind the substance to be trapped contained in the sample to the affinity substance on the affinity support.
- one objective to be trapped is a single molecule.
- one objective to be trapped is one dimer or higher-order multimer composed of two or more molecules or one aggregate.
- two or more affinity sites that is, sites that specifically bind to the affinity substance(s) are present.
- the use of the affinity support according to the present invention makes it possible to simultaneously bind at least two affinity substances to at least two of the two or more affinity sites present in one objective to be trapped (i.e., to achieve cooperative binding).
- cooperative binding it is not required that simultaneous binding to the at least two affinity sites should be always achieved. For example, there may be a moment when only one of the at least two affinity sites is bound to the affinity substance. That is, cooperative binding allows any one of the two or more affinity sites of the substance to be trapped to be always bound to the affinity substance, which makes it easy to keep a state where the substance to be trapped is trapped by the affinity substance. In other words, complete dissociation between the substance to be trapped and the affinity substance is less likely to occur.
- the association rate constant ka (unit: 1/Ms) for binding of the affinity substance is comparable to the association rate constant ka of a conventional common molecular recognition system.
- the dissociation rate constant kd (unit: 1/s) for binding of the affinity substance is lower than that for the conventional common molecular recognition system.
- the dissociation constant KD (unit: M) for binding of the affinity substance is smaller than that for the conventional common molecular recognition system, and is, for example, 10 ⁇ 7 , 10 ⁇ 8 , 10 ⁇ 9 , 10 ⁇ 10 , 10 ⁇ 11 , or 10 ⁇ 12 at the maximum and may be, for example, 10 ⁇ 13 to 10 ⁇ 7 .
- one objective to be trapped is a single molecule
- two or more affinity sites are present in the single molecule.
- the two or more affinity sites present in the single molecule are generally different from each other. Therefore, two or more different kinds of the affinity substances need to be bound to the affinity support so that the affinity substances can bind to at least two affinity sites simultaneously.
- one objective to be trapped is composed of two or more molecules, at least one affinity site needs to be present in each of the molecules.
- two or more molecules constituting one objective to be trapped are generally the same, and therefore have the same at least one affinity site. Therefore, one kind of the affinity substance is bound to the affinity support.
- the possibility that two or more kinds of the affinity substances are bound to the affinity support is not particularly excluded.
- An objective to be trapped by the affinity support according to the present invention can be easily determined by those skilled in the art depending on the kind of affinity substance bound thereto or the combination of different kinds of the affinity substances bound thereto.
- the objective to be trapped may or may not have a naturally-derived structure.
- the objective to be trapped include biological substances, especially polypeptides, sugar chains, nucleic acids, and conjugates of two or more of them (e.g., conjugates obtained by arbitrarily combining two or more of them such as glycopeptides and peptide nucleic acids).
- biological substances may have a molecular weight of, for example, 200 to 1,000,000, preferably 1,000 to 200,000.
- a more specific example of the objective to be trapped is a biological substance selected from the group consisting of a biomarker, a biomarker candidate molecule, and a fragment generated from a biomarker or a biomarker candidate molecule by splicing.
- the biomarker may be one related to a disease selected from the group consisting of cancer, brain disease (e.g., Alzheimer's disease), heart disease, immune disease, hepatic disease, renal disease, and eye disease.
- the affinity support can trap the surface antigen of a virus.
- the affinity support according to one embodiment of the present invention having two to five kinds of the affinity substances bound thereto can easily respond to variations of a virus that may be created by varying its surface antigen.
- the affinity support can trap, for example, a receptor constituting a dimer or higher-order multimer such as a vascular endothelial cell growth factor receptor (VEGFR), an epidermal growth factor receptor (EGFR), or a tumor necrosis factor receptor (TNFR).
- VEGFR vascular endothelial cell growth factor receptor
- EGFR epidermal growth factor receptor
- TNFR tumor necrosis factor receptor
- non-biological substance especially an environmentally hazardous substance.
- the environmentally hazardous substance include compounds such as dioxin, estrogen, polychlorinated biphenyl, and the like.
- the non-biological substance may be a low molecular weight compound having a molecular weight of 100 to 1,000, preferably 200 to 700.
- Another specific example of the objective to be trapped is a multimer or aggregate of drug molecules.
- the present invention is useful also when association or aggregation of drug molecules becomes a problem during drug preparation.
- drug molecules having the risk of causing such a problem are polypeptide drug molecules. Therefore, examples of such drug molecules include polypeptide drug molecules, and specific examples of the polypeptide drug molecules include insulin, parathyroid hormone and the like.
- a sample to be subjected to the affinity support is not particularly limited as long as it contains the above-described objective to be trapped.
- the sample is usually prepared in a liquid state.
- the objective to be trapped contained in the sample does not always need to be purified.
- the degree of purification is not an issue.
- the degree of treatment such as purification performed on the objective to be trapped contained in the sample is preferably low.
- Examples of the sample to be subjected to the affinity support include biological samples prepared from cells, tissues, body fluids, secretions, and excretions of organisms.
- a typical biological sample prepared from a body fluid is a blood-derived sample.
- Examples of the blood-derived sample include whole blood, blood plasma, and blood serum.
- An example of operation that can be performed when a blood-derived sample is prepared from a body fluid is removal of blood cells (more specifically, red blood cells, white blood cells, and/or blood platelets) by centrifugation after addition of an anticoagulant agent (e.g., ethylenediamine tetra-acetic acid, citric acid, or heparin) to blood.
- an anticoagulant agent e.g., ethylenediamine tetra-acetic acid, citric acid, or heparin
- Another example of operation that can be performed during preparation of a blood-derived sample is removal of a blood coagulation factor and blood cells after blood coagulation and centrifugation. It is well known that blood undergoes a dynamic change in its components due to the occurrence of disease. Therefore, the blood-derived sample can be used for early diagnosis, follow-up, and/or follow-up after treatment of various diseases by using molecules whose blood levels vary as biomarkers. Further, novel marker molecules in blood have the potential to achieve early diagnosis and high-accuracy diagnosis in the future. Therefore, the blood-derived sample can also be used to search novel marker molecules in blood for the purpose of developing a novel diagnostic method.
- sample to be subjected to the affinity support is an environmental sample prepared from an environmental substance.
- environmental substance include soil, strata, water, air, and the like.
- An example of operation that can be performed when an environmental sample is prepared from an environmental substance is extraction using an organic solvent (e.g., acetone or toluene).
- sample to be subjected to the affinity support is an unpurified drug sample.
- an unpurified drug sample By subjecting such a drug sample to the affinity support, it is possible to remove unnecessary substances (multimers and aggregates of drug molecules) contained in the sample to obtain a purified drug.
- the concentration of the objective to be trapped contained in the sample may be, for example, 1 to 10 12 amol/mL, preferably 100 to 10′ amol/mL.
- the sample can be subjected to the affinity support in such a manner that the amount of the objective to be trapped is 0.1 to 500 pmol, preferably 1 to 100 pmol per 1 cm 2 of the surface of the support.
- the surface of the support may be subjected to a washing process.
- the washing process can be performed by subjecting the surface of the support to a fluid pressure of 0.01 to 500 MPa, preferably 0.05 to 300 MPa, more preferably 0.1 to 200 MPa to remove unnecessary components. If the fluid pressure is less than the above lower limit, a desired washing effect is less likely to be obtained. If the fluid pressure exceeds the above upper limit, there is a fear that binding between the affinity substance and the trapped objective is cleaved.
- the affinity support according to the present invention can hold an objective to be trapped by cooperative binding, and therefore can be washed under higher pressure conditions as compared to when a conventional affinity support is used. Such expansion of washing conditions improves the removal efficiency of substances non-specifically adsorbed to the affinity support, which as a result contributes to an improvement in the sensitivity of analysis of the trapped objective.
- a specific washing method is not particularly limited.
- the affinity support when having a spherical shape, can be washed by vigorously stirring said affinity support in a washing liquid.
- the affinity support when having a planar shape, can be washed by spraying said affinity support with a high-pressure washing liquid discharged from a spray nozzle. More specifically, in order to subject the specific region on the planar-shaped support to high-pressure washing, a spray nozzle having an inner diameter corresponding to the area of the specific region can be used.
- This nozzle is constituted from, for example, a double pipe, and an inner pipe can function only as an injection pipe for spraying the surface of the support with a washing liquid, and an outer pipe can function only as a drain pipe for sucking the washing liquid sprayed onto the surface of the support.
- the trapped objective can be analyzed by an appropriate detection system in a state where said trapped objective remains bound to the affinity support, or said trapped objective is collected by elution from the affinity support (i.e., by releasing the trapped objective by cleaving the binding between the trapped objective and the affinity substance).
- the elution of the trapped objective from the affinity support can be performed by subjecting the affinity support bound to the trapped objective to an eluate that can be easily selected by those skilled in the art depending on the combination of the trapped objective and the affinity substance.
- radioactive assay enzyme activity assay, fluorescence intensity assay, or emission intensity assay can be used.
- adetection system based on any solid phase immunoassay may be selected.
- a detection system based on radioimmunoassay (RIA), enzyme immunoassay (EIA, ELISA), fluorescence immunoassay (FIA), chemiluminescent immunoassay (CLIA), or the like is selected.
- a label selected from the group consisting of radioisotope, enzyme, fluorescent substance, and chemiluminescent substance
- the detection system used can be based on the detecting method used in the above-described immune system.
- the use of the aptamer-receptor protein system is preferred because the aptamer-receptor protein system is superior to the above-described immune system in specific binding ability and ease of aptamer preparation.
- an optical detection system based on surface Plasmon resonance (SPR), sum frequency generation (SFG), local Plasmon resonance (LPR), ellipsometry, or the like is used. Unlike the above-described detection system, such an optical detection system does not require a label.
- a detection system based on mass spectrometry is used as another preferred example of the detection system other than the above-described detection system.
- a detection system based on mass spectrometry is used as another preferred example of the detection system other than the above-described detection system.
- MALDI Matrix Assisted Laser Desorption/Ionization
- a MALDI-TOF (Matrix Assisted Laser Desorption/Ionization-Time of Flight) mass spectrometer for example, a MALDI-TOF (Matrix Assisted Laser Desorption/Ionization-Time of Flight) mass spectrometer, a MALDI-IT (Matrix Assisted Laser Desorption/Ionization-Ion Trap-Time of Flight) mass spectrometer, a MALDI-FTICR (Matrix Assisted Laser Desorption/Ionization-Fourier Transform Ion Cyclotron Resonance) mass spectrometer, or the like can be used.
- a matrix and a matrix solvent can be easily determined by those skilled in the art depending on the kind of objective to be analyzed (i.e., depending on the kind of objective trapped by the affinity support).
- ⁇ -cyano-4-hydroxycinnamic acid 2,5-dihydroxybenzoic acid, sinapic acid, 3-aminoquinoline, or the like can be used.
- the matrix solvent to be used can be selected from, for example, the group consisting of acetonitrile (ACN), trifluoroacetic acid (TFA), methanol, ethanol, and water. More specifically, an aqueous ACN-TFA solution, an aqueous ACN solution, an aqueous methanol-TFA solution, an aqueous methanol solution, an aqueous ethanol-TFA solution, an ethanol solution, or the like can be used.
- the concentration of ACN in the aqueous ACN-TFA solution may be, for example, 10 to 90 vol % and the concentration of TFA may be, for example, 0.05 to 1 vol %, preferably 0.05 to 0.1 vol %.
- the concentration of the matrix may be, for example, 0.1 to 50 mg/mL, preferably 0.3 to 20 mg/mL, more preferably 0.5 to 20 mg/mL.
- a matrix additive (co-matrix) is preferably used in combination with the matrix.
- the matrix additive can be appropriately selected by those skilled in the art depending on the kind of objective to be analyzed and/or the kind of matrix to be used.
- a phosphonic acid group-containing compound can be used as the matrix additive.
- Specific examples of a compound containing one phosphonic acid group include phosphonic acid, methylphosphonic aid, phenylphosphonic acid, 1-naphthylmethylphosphonic acid, and the like.
- a compound containing two or more phosphonic acid groups include methylenediphosphonic acid, ethylenediphosphonic acid, ethane-1-hydroxy-1,1-diphosphonic acid, nitrilotriphosphonic acid, ethylenediaminetetraphosphonic acid, and the like.
- phosphonic acid group-containing compounds those containing two or more phosphonic acid groups, preferably 2 to 4 phosphonic acid groups in one molecule are preferred.
- the use of the phosphonic acid group-containing compound is useful, for example, when an oxyalkylene group-containing group is used as the spacer.
- the oxyalkylene group-containing group has the property of incorporating positively-charged metal ions around its oxygen atoms, but the metal ions adversely affect the background in mass spectrometry.
- the use of the phosphonic acid group-containing compound has the effect of reducing such an adverse effect.
- a more common additive selected from, for example, the group consisting of ammonium salt and organic base may be used.
- the matrix additive can be prepared as a 0.1 to 10 w/v %, preferably 0.2 to 4 w/v % aqueous solution or matrix solvent solution.
- a matrix additive solution and a matrix solution can be mixed in a volume ratio of, for example, 1:100 to 100:1, preferably 1:10 to 10:1.
- the present invention will be described more specifically with reference to examples, but is not limited to the following examples.
- the amount of a substance expressed as “%” is based on weight when the substance is solid and on volume when the substance is liquid unless otherwise specified.
- Example 1 Trapping of Amyloid ⁇ (1-42) by F(ab′)-PEGn Beads Using One Kind of Antibody Fragment
- FIG. 1 A procedure for preparing 6E10 F(ab′)-PEGn beads is schematically shown in FIG. 1 .
- antibody F(ab′) fragments were prepared. More specifically, 250 ⁇ g of anti-amyloid ⁇ antibody (6E10) whose epitope includes residues 3 to 8 of amyloid ⁇ was digested with 1,250 ⁇ L of Ficin agarose beads (Thermo) (33% slurry), and a Ficin digest was separated by size exclusion chromatography.
- FIG. 2 shows the result of separation of the Ficin digest of 6E10 by size exclusion chromatography.
- FIG. 3A shows the image of a gel obtained by reducing SDS-PAGE chromatography of the fractionated digest of 6E10
- FIG. 3B shows the image of a gel obtained by non-reducing SDS-PAGE chromatography of the fractionated digest of 6E10.
- FIG. 4 shows size exclusion chromatograms of the F(ab′) 2 fraction before reduction treatment ( FIG. 4A ) and after reduction treatment ( FIG. 4B ). It was confirmed from FIG. 4 that 6E10 F(ab′) was generated by reduction of the 6E10 F(ab′) 2 fraction.
- IgG-protein G beads were prepared by affinity binding of 0.75 ⁇ g of 6E10 IgG to 5 ⁇ L of protein G magnetic beads (Dynabeads Protein G: Invitrogen) (33% slurry).
- amyloid ⁇ (1-42) As an antigen, amyloid ⁇ (1-42) was used. It is known that C-terminus of amyloid ⁇ (1-42) aggregates to form multimers. Therefore, one amyloid ⁇ (1-42) aggregate has two or more epitopes for 6E10, and therefore can be used as a material suitable for evaluation of the binding strength of cooperative binding. It is to be noted that the aggregation of amyloid ⁇ (1-42) used in this example was confirmed by SDS-PAGE. Amyloid ⁇ (1-42) whose concentration was 3 to 100 ⁇ g/mL was separated by SDS-PAGE, and the gel was stained with silver. The image of the gel is shown in FIG. 5 . As shown in FIG. 5 , monomers, trimers, and tetramers of amyloid ⁇ (1-42) were detected.
- a carbonate buffer 15 mM Na 2 CO 3 , 35 mM NaHCO 3 , pH 9.6
- the wells were washed with 300 ⁇ L/well of a washing buffer (10 mM Na 2 HPO 4 , 1.76 mM KH 2 PO 4 , 137 mM NaCl, 2.7 mM KCl, 0.1% Tween) three times.
- a washing buffer (10 mM Na 2 HPO 4 , 1.76 mM KH 2 PO 4 , 137 mM NaCl, 2.7 mM KCl, 0.1% Tween) three times.
- a reaction buffer 10 mM Na 2 HPO 4 , 1.76 mM KH 2 PO 4 , 137 mM NaCl, 2.7 mM KCl, 0.1% Tween, 5% blocking buffer (Nacalai Tesque)
- the wells were washed with 300 ⁇ L/well of the washing buffer five times, and then a 0.1 ⁇ g/mL HPR-labeled anti-amyloid ⁇ antibody (6E10-HPR) was placed in the wells in an amount of 100 ⁇ L/well and shaken at room temperature for 1 hour.
- the wells were washed with 300 ⁇ L/well of a washing buffer (PBS-0.1% Tween) five times, and then TMB was placed in the wells in an amount of 100 ⁇ L/well and shaken at room temperature for 15 minutes. After 1N H 2 SO 4 was added to the wells in an amount of 100 ⁇ L/well, absorbance (450 nm/650 nm) of the wells was measured using a plate reader.
- Isolation and concentration of amyloid ⁇ (1-42) were performed using the different kinds of beads (i.e, 6E10 F(ab′)-PEG 24 beads, 6E10 F(ab′)-PEG 2 beads, and 6E10 IgG-protein G beads) under conditions where the amount of amyloid ⁇ (1-42) as an antigen was set to a fixed value of 100 ng, the number of the beads of each kind was set to a fixed value of 10 7 , and the liquid amounts of a reaction solution were set to 10, 100, and 1,000 ⁇ L (i.e., variations of concentration levels of antibody and antigen were 1 ⁇ , 10 ⁇ , and 100 ⁇ ). The amount of the antigen trapped for isolation and concentration was measured by ELISA.
- a graph representing the amount of trapped amyloid ⁇ (1-42) is shown in FIG. 6 .
- the amount of the antigen trapped by the 6E10 F(ab′)-PEG 24 beads was 5.9 to 8.5 times larger than that trapped by the 6E10 IgG-protein G beads, and the amount of the antigen trapped by the 6E10 F(ab′)-PEG 2 beads was 5.6 to 6.9 times larger than that trapped by the 6E10 IgG-protein G beads.
- FIG. 7 shows the MALDI-TOF MS spectra of amyloid ⁇ (1-42) eluates obtained when the 6E10 IgG-protein G beads were used ( FIG. 7A ), the MALDI-TOF MS spectra of amyloid ⁇ (1-42) eluates obtained when the 6E10 F(ab′)-PEG 2 beads were used ( FIG. 7A ), the MALDI-TOF MS spectra of amyloid ⁇ (1-42) eluates obtained when the 6E10 F(ab′)-PEG 2 beads were used ( FIG.
- the detection level achieved by the method according to the present invention was equivalent to the detection limit achieved by directly spotting amyloid ⁇ (1-42) onto a MALDI plate. That is, the method according to the present invention makes it possible to collect amyloid ⁇ (1-42) from a sample at a rate nearly 100%.
- Example 2 Trapping of Amyloid ⁇ (1-28) by 6E10/4G8 F(Ab′)-PEGn Beads Using Two Kinds of Antibody Fragments
- the amount of the trapped objective can be increased when the 6E10 F(ab′)-PEGn beads of Example 1 derived from one kind of antibody are used as compared to when the 6E10 IgG-protein G beads are used.
- beads having two kinds of F(ab′) fragments were prepared based on the premise that, when a single molecule of an antigen is an objective to be trapped, at least two kinds of antibody-derived F(ab′) fragments that recognize two or more sites in the antigen single molecule are necessary to increase the amount of the trapped antigen.
- F(ab′) fragments were prepared in the same manner as in Example 1 from anti-amyloid ⁇ antibody 6E10 whose epitope includes 3-8 residues of amyloid R, and the other was prepared from anti-amyloid ⁇ antibody 4G8 whose epitope includes 18-22 residues of amyloid ⁇ .
- the 4G8 antibody is an IgG2b, and therefore F(ab′) 2 cannot be obtained by Ficin or Pepsin. For this reason, F(ab′) 2 was obtained by lysyl-end peptidase (LysC). More specifically, 100 ⁇ g of 4G8 was digested with 500 ng of LysC for 2.5 hours, and then a LysC digest was separated by size exclusion chromatography.
- FIG. 8 shows the result of separation of the LysC digest of 4G8 by size exclusion chromatography.
- FIG. 9 shows the image of a gel obtained by reducing SDS-PAGE chromatography of the fractionated digest of 4G8 ( FIG. 9A ) and the image of a gel obtained by non-reducing SDS-PAGE chromatography of the fractionated digest of 4G8 ( FIG. 9B ).
- the fractions 16-29 showing a band at about 150 kDa under non-reducing conditions and at 25 kDa under reducing conditions were collected as a 4G8 F(ab′) 2 fraction.
- the 4G8 F(ab′) 2 fraction was reduced to obtain 4G8 F(ab′).
- Example 2 For reference experiments, the same 6E10 F(ab′)-PEG 24 beads as used in Example 1 were prepared, and 4G8 F(ab′)-PEG 24 beads were prepared in the same manner as in (1) in Example 1 except that the 4G8 F(ab′) fraction was used as the F(ab′) fraction.
- Protein G beads to each of which two kinds of antibodies were bound that is, 6E10/4G8 IgG-protein G beads were prepared in the same manner as in (2) in Example 1 except that the 4G8 IgG and the 6E10 IgG were used in 1:1 (molar ratio).
- Example 1 For control experiments, the same 6E10 IgG-protein G beads as used in Example 1 were prepared, and 4G8 IgG-protein G beads were prepared in the same manner as in (2) in Example 1 except that 4G8 IgG was used as the antibody.
- amyloid ⁇ (1-28) was used as an antigen.
- Amyloid ⁇ (1-28) is present as a single molecule and an aggregate in a solution.
- Amyloid ⁇ (1-28) was trapped in the same manner as in (4) in Example 1 using the above-described affinity beads (6E10/4G8 F(ab′)-PEG 24 beads, 6E10 F(ab′)-PEG 24 beads, 4G8 F(ab′)-PEG 24 beads, 6E10/4G8 IgG-protein G beads, 6E10 IgG-protein G beads, and 4G8 IgG-protein G beads). Further, MALDI-TOF MS was performed using a mass spectrometer in the same manner as in (6) in Example 1 to determine detection limits. FIG.
- FIG. 10 shows the MALDI-TOF MS spectra of amyloid ⁇ (1-28) eluates obtained when the 6E10 IgG-protein G beads were used ( FIG. 10A ), the MALDI-TOF MS spectra of amyloid ⁇ (1-28) eluates obtained when the 4G8 IgG-protein G beads were used ( FIG. 10B ), the MALDI-TOF MS spectra of amyloid ⁇ (1-28) eluates obtained when the 6E10/4G8 IgG-protein G beads were used ( FIG. 10C ), the MALDI-TOF MS spectra of amyloid ⁇ (1-28) eluates obtained when the 6E10 F(ab′)-PEG 24 beads were used ( FIG.
- the detection limit was 25 ⁇ g in all the cases.
- the 6E10 F(ab′)-PEG 24 beads were used, the detection limit was 5 ⁇ g. That is, sensitivity when the 6E10 F(ab′)-PEG 24 beads were used was 5 times higher than that when the IgG-protein G beads of each kind were used. It is considered that this is because space is created between each of the beads and ⁇ F(ab′) by PEG insertion so that steric hindrance becomes less likely to occur and the binding strength of antigen-antibody reaction is enhanced.
- the detection limit when the 4G8 F(ab′)-PEG 24 beads were used was 25 ⁇ g that was the same as that when the 4G8 IgG-protein G beads were used.
- F(ab′) fragmentation of IgG reduces the binding strength between antigen and antibody, but it has been found that the effect of PEG insertion to enhance the binding strength between antigen and antibody can compensate for a reduction in the binding strength between antigen and antibody due to the fragmentation of IgG.
- the detection limit was 2.5 ⁇ g, which was equivalent level to the detection limit achieved by directly spotting amyloid ⁇ (1-28) onto a MALDI plate.
- the detection limit when the 6E10/4G8 F(ab′)-PEG 24 beads are used is estimated to be about 15 ⁇ g that is the average of the detection limit when the 6E10 F(ab′)-PEG 24 beads were used (5 ⁇ g) and the detection limit when the 4G8 F(ab′)-PEG 24 beads were used (25 ⁇ g).
- the detection limit when the 6E10/4G8 F(ab′)-PEG 24 beads were used was 2.5 ⁇ g that was 1/6 of the estimated detection limit.
- One milliliter of a sample was prepared by spiking 1 ng (307 fmol) of amyloid ⁇ (1-28) in plasma obtained by diluting 50 ⁇ L of human plasma 20-fold with TBS-1% OTG.
- Amyloid ⁇ (1-28) in the sample was isolated and concentrated in the same manner as in (4) in Example 1.
- washing with TBS-1% OTG performed in Example 1 three times after the reaction between the beads and the sample was performed 5 times to eliminate impurities non-specifically adsorbed to the beads.
- amyloid ⁇ (1-28) was isolated and concentrated using the 6E10 F(ab′)-PEG 24 beads, and was then analyzed by a mass spectrometer in the same manner as in (6) in Example 1. The thus obtained mass spectrum is shown in FIG. 11(A) . As shown in FIG. 11(A) , many peaks other than the peak of amyloid ⁇ (1-28) were detected.
- HAMA human anti-mouse antibody
- 6E10 and 4G8 are mouse-derived IgGs, molecules of such an antibody bind thereto.
- human anti-mouse antibody contained in the plasma was removed by mixing the plasma sample and 50 ⁇ L of protein G agarose and incubating the mixture at 4° C. for 30 minutes. Then, mass spectrometry was performed in the same manner. The thus obtained mass spectrum is shown in FIG. 11(B) . As shown in FIG. 11(B) , the many peaks other than the peak of amyloid ⁇ (1-28) were removed by removing human anti-mouse antibody. On the other hand, a high background spectrum was observed.
- PEG has the property of incorporating positively-charged metal ions around negatively-charged oxygen atoms thereof.
- metal ions contained in the reaction buffer and the plasma have an influence on analysis performed by the mass spectrometer. It is considered that this influence causes a high background in the mass spectrum. For this reason, 1 ⁇ L of a 2% aqueous methanediphosphonic acid (MDPNA) solution having the effect of reducing the background due to metal ions was mixed as a comatrix on the MALDI plate, and then mass spectrometry was performed.
- MDPNA 2% aqueous methanediphosphonic acid
- FIG. 12 shows the MALDI-TOF MS spectra of amyloid ⁇ (1-28) eluates obtained when the 6E10 IgG-protein G beads were used ( FIG. 12A ), the MALDI-TOF MS spectra of amyloid ⁇ (1-28) eluates obtained when the 4G8 IgG-protein G beads were used ( FIG. 12A ), the MALDI-TOF MS spectra of amyloid ⁇ (1-28) eluates obtained when the 4G8 IgG-protein G beads were used ( FIG.
- FIG. 12B the MALDI-TOF MS spectra of amyloid ⁇ (1-28) eluates obtained when the 6E10/4G8 IgG-protein G beads were used
- FIG. 12C the MALDI-TOF MS spectra of amyloid ⁇ (1-28) eluates obtained when the 6E10 F(ab′)-PEG 24 beads were used
- FIG. 12D the MALDI-TOF MS spectra of amyloid ⁇ (1-28) eluates obtained when the 4G8 F(ab′)-PEG 24 beads were used
- the evaluation point of this example is to achieve a mass spectrometric detection level close to 1 ⁇ g (307 amol) by isolating and concentrating amyloid ⁇ (1-28) in plasma using the F(ab′)-PEG 24 beads. It is to be noted that a detection limit of 1 ⁇ g (307 amol) achieved in this example is lower than that achieved in Example 2 using only the matrix CHCA. This is because the combined use of the matrix and the comatrix MDPNA reduces the background, which increases the S/N ratio.
- Amyloid ⁇ (1-28) spiked in plasma was isolated and concentrated using the three kinds of F(ab′)-PEG 24 beads (6E10 F(ab′)-PEG 24 beads, 4G8 F(ab′)-PEG 24 beads, and 6E10/4G8 F(ab′)-PEG 24 beads) and the three kinds of IgG-protein G beads (6E10-protein G beads, 4G8-protein G beads, and 6E10/4G8-protein G beads).
- the lowest level of amyloid ⁇ (1-28) (1 ⁇ g) could be detected when the 6E10/4G8 F(ab′)-PEG 24 beads were used.
- the detection level achieved in this case was equivalent to that when pure amyloid ⁇ (1-28) was analyzed by the mass spectrometer.
- the S/N ratio when the 6E10/4G8 F(ab′)-PEG 24 beads were used was lower than that when pure amyloid ⁇ (1-28) was analyzed, from which it is considered that the eluate contained minute quantities of impurities.
- Example 2 Also among the three kinds of IgG-protein G beads, there was a difference in detection limit. Among them, the lowest level of amyloid ⁇ (1-28) (5 ⁇ g) could be detected when the 6E10/4G8 IgG-protein G beads were used. On the other hand, in Example 2, there was no difference in detection limit among the three kinds of IgG-protein G beads, but it was confirmed that the S/N ratio was highest when the 6E10/4G8 IgG-protein G beads were used.
- Example 3 the probable reason why a low level of amyloid ⁇ (1-28) could be detected when the 6E10/4G8 IgG-protein G beads were used is that also when the protein G beads to which the two kinds of antibodies were bound were used, cooperative binding was achieved by the F(ab′) fragments of the different antibodies.
- the Non-Patent Document 2 (Proceedings of the Japan Academy, Ser. B, Physical and biological Sciences 2011; 87(9):603-16) states that the K D value of the amyloid ⁇ (1-15)-Fc6 antibody-like molecule in which PEG is not inserted into the hinge region is lower than that of amyloid ⁇ (1-15) peptide, that is, the amyloid ⁇ (1-15)-Fc6 antibody-like molecule in which PEG is not inserted into the hinge region is less likely to cause dissociation of anti-amyloid ⁇ antibody than amyloid ⁇ (1-15) peptide.
- the Non-Patent Document 2 suggests that cooperative binding can be achieved also when the hinge region of the antibody-like molecule is the original hinge region of IgG (to which no PEG is inserted). This is suggested also by the result of SPR analysis.
- Non-Patent Document 2 also states that the K D value of the antibody-like molecule having a hinge region into which PEG is inserted is lower than that of the antibody-like molecule having a hinge region into which PEG is not inserted.
- the tendency that the K D value is lowered by PEG insertion is seen also in the result of this example that the amount of the trapped antigen was larger when the 6E10/4G8 F(ab′)-PEG 24 beads were used than when the 6E10/4G8 IgG-protein G beads were used.
- the maximum binding amount (Rmax) of the amyloid ⁇ (1-15)-PEG 24 -Fc6 antibody-like molecule is 40 when the Rmax of the amyloid ⁇ (1-15)-Fc6 antibody-like molecule is 34.9.
- the tendency that the binding amount is increased by PEG insertion is also in accordance with the result of this example.
- FIG. 13 shows a mass spectrum obtained by analyzing, with a mass spectrometer, an eluate obtained by isolating and concentrating 1 ⁇ g (307 amol) of amyloid ⁇ (1-28) spiked in plasma using the 6E10/4G8 F(ab′)-PEG 24 beads.
- FIG. 13 shows that when the 6E10/4G8 F(ab′)-PEG 24 beads were used, no peaks (S/N ⁇ 3) other than the peak of amyloid ⁇ (1-28) were detected in the range of m/z 1,500 to 5,000.
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Analytical Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Optics & Photonics (AREA)
- Neurology (AREA)
- Inorganic Chemistry (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Plasma & Fusion (AREA)
- Neurosurgery (AREA)
- Solid-Sorbent Or Filter-Aiding Compositions (AREA)
- Peptides Or Proteins (AREA)
- Treatment Of Liquids With Adsorbents In General (AREA)
- Sampling And Sample Adjustment (AREA)
- Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
- Materials For Medical Uses (AREA)
Abstract
Description
- This application is a continuation of U.S. application Ser. No. 14/414,329, filed Jan. 12, 2015, now allowed, which is a § 371 national stage of PCT International Application No. PCT/US2013/043875, filed Jun. 3, 2013, claiming priority of Japanese Patent Application No. JP 2012-158647, filed Jul. 17, 2012, the contents of each of which are hereby incorporated by reference herein.
- The present invention relates to high-sensitivity measurement and/or structural analysis of molecules contained in a biological sample or the like. The present invention relates to initial diagnosis of diseases, follow-up of diseases, and/or a technique for evaluating chemotherapeutic sensitivity.
- As methods for isolating a specific polypeptide (peptide or protein) from a biological sample such as a cell extract, a tissue extract, or a body fluid (e.g., blood, urine, or spinal fluid), a method using chromatography and a method using molecules having the ability of specific binding, that is, affinity molecules are used.
- Examples of the method using chromatography include a method using reverse phase chromatography and a method using ion-exchange chromatography.
- Examples of the method using affinity molecules include a method using an affinity support.
- For example, Patent Document 1 (JP 7-268000 A) discloses an immune adsorbent composed of a carrier and an antibody bound to the carrier, and describes that the immune adsorbent can be prepared using a polyclonal antibody or a monoclonal antibody as the antibody, and using a crosslinking agent such as N,N′-hexamethylenebismaleimide in order to bind the antibody to the carrier.
- Generally, as a method for isolating a target protein from a biological sample, an immunoprecipitation method using protein A/G beads is used. For example, Non-Patent Document 1 (Analytical Biochemistry 1999 Nov. 15; 275(2): 262-5) discloses semiquantitative analysis of amyloid β peptides using a combination of immunoprecipitation and MALDI mass spectrometry.
- Further, for example, Non-Patent Document 2 (Proceedings of the Japan Academy, Ser. B, Physical and Biological Sciences 2011; 87(9): 603-16) describes a preparation of a flexible antibody-like molecule composed of an antibody Fc fragment, a hinge region bound to the antibody Fc fragment and having polyethylene glycol, and amyloid β bound to the hinge region.
- Non-Patent
Document 2 describes that a molecule having two amyloid β peptides (i.e., a two-handed molecule) and a molecule having one amyloid β peptide (i.e., a one-handed molecule) are obtained by the preparation. Further, Non-PatentDocument 2 describes that when anti-amyloid β antibody is an objective to be trapped, binding between the two-handed molecule and anti-amyloid β antibody achieves a lower dissociation constant KD than binding between the one-handed molecule and anti-amyloid β antibody. - It is to be noted that Patent Document 2 (WO2005/037881) describes that a carrier prepared by fixing a ligand to a resin obtained by polymerization of a monomer component having a hydrophilic spacer inserted therein is used to reduce non-specific adsorption to the carrier.
-
- Patent Document 1: JP 7-268000 A
- Patent Document 2: WO2005/037881
-
- Non-Patent Document 1: Analytical Biochemistry 1999 Nov. 15; 275(2): 262-5
- Non-Patent Document 2: Proceedings of the Japan Academy, Ser. B, Physical and Biological Sciences 2011; 87(9): 603-16
- The method using chromatography performs separation and concentration of a target polypeptide in a stepwise fashion using several kinds of carriers, and therefore inevitably requires a large amount of biological sample.
- The method using affinity molecules can isolate a target polypeptide in a single treatment due to specific binding achieved by the affinity between molecules, and therefore requires only a minute amount of biological sample. From such a viewpoint, the method using affinity molecules makes up for the shortcomings of the method using chromatography in terms of the amount of a biological sample required. Further, the method using affinity molecules requires less time and is versatile.
- However, in the case of the methods using affinity molecules disclosed in
Patent Document 1 andNon-Patent Document 1, the collection rate of a target molecule (e.g., a polypeptide) and the amount of incorporated impurities depend on the properties of an affinity carrier (e.g., an immune adsorbent or protein A/G beads). For example, when the affinity carrier is one using an antibody, the efficiency of trapping a target molecule or the amount of non-specifically adsorbed impurities depends on the titer of the antibody. Such limitations inevitably imposed by the properties of the affinity carrier lead to limitations of analytical sensitivity or specificity in mass spectrograph or SDS-PAGE of the target molecule collected by the affinity carrier. Such a problem often results in difficulty in analysis particularly in researches on minute amounts of biomolecules. - The method disclosed in
Patent Document 2 is limited to applications using ligands and merely reduces non-specific adsorption, and therefore cannot specifically trap specific target molecules. - In the case of the method using affinity molecules disclosed in
Non-Patent Document 2, it is considered that PEG inserted into the hinge region of an antibody provides an appropriate interval between two amyloid β peptides (1-15), which makes it possible to simultaneously bind the two amyloid β peptides (1-15) to two F(ab) regions of 6E10, respectively. Thus, it is considered that by binding of one two-handed molecule to one molecule via both two hands of said two-handed molecule (in the present specification, referred to as “cooperative binding”), a binding (with a 100 to 100,000 times lower dissociation constant KD) that is less likely to cause dissociation than binding of one one-handed molecule to one molecule via only one hand of said one-handed molecule is achieved. A binding mode in which one one-handed molecule binds to one molecule via only one hand of said one-handed molecule is the same as that in which a normal antibody binds to an objective to be trapped by the antibody. From such a viewpoint, binding with a low dissociation constant KD, that is, cooperative binding achieved by the method disclosed in Non-PatentDocument 2 is expected to make up for the shortcomings of the methods disclosed inPatent Document 1 andNon-Patent Document 1 in terms of the titer of antibody. - However, in the method disclosed in
Non-Patent Document 2, the objective to be trapped that can be bound to the antibody-like molecule by cooperative binding is only an antibody molecule (anti-amyloid β antibody molecule (6E10)) similar to the antibody-like molecule in size and shape. That is, Non-PatentDocument 2 does not suggest the possibility of achieving cooperative binding between the antibody-like molecule and various molecules other than antibodies, especially polypeptides, which are different in size and shape and may be generally objectives to be trapped by affinity carriers. - A mass spectrometer is a powerful tool for structural analysis of biomolecules. However, in order to perform structural analysis of molecules contained in a biological sample using a mass spectrometer, biomolecules as an objective to be analyzed contained in the biological sample need to be concentrated. This is because a mass spectrometer has a limitation in its detectable level, and therefore an objective to be analyzed in a sample subjected to mass spectrometry needs to be concentrated to a detectable level. In addition to the necessity for concentrating an objective to be analyzed, impurities other than the objective to be analyzed need to be removed. This is because impurities contained in a sample subjected to mass spectrometry cause an increase in the background of data or ion suppression that interferes with the detection of the objective to be analyzed.
- It is therefore an object of the present invention to provide an affinity support capable of, even when an objective to be trapped contained in a sample is a molecule other than an antibody, isolating and concentrating the objective by trapping via cooperative binding (i.e., isolating the objective from the sample in a concentrated state) and a trapping method using the same.
- The present invention includes the following inventions.
- (1) An affinity support comprising a support, a spacer bound to the support and an affinity substance bound to the spacer, wherein two to five kinds of the affinity substance bound to the spacer exist in a mixed state.
- One specific example of the affinity support according to the above (1) will be described with reference to Example 2.
- (2) The affinity support according to the above (1), wherein the length of the spacer is 1 to 100 nm.
- (3) The affinity support according to the above (1) or (2), wherein the spacer comprises an oxyalkylene group.
- (4) The affinity support according to the above (1) or (2), wherein the spacer is selected from the group consisting of a polyalkylene glycol, a polyoxyalkylated polyol, a polyvinyl alcohol, a polyvinyl alkyl ether, a polysaccharide, a biodegradable polymer, and a lipopolymer.
- (5) The affinity support according to any of the above (1) to (4), wherein the spacer is branched, the support is bound to a main chain of the spacer, and the affinity substance is bound to a branched chain of the spacer.
- (6) The affinity support according to any of the above (1) to (5), wherein an interval between binding positions on the support of the spacers bound to the affinity substances is 1 to 50 angstrom (Å).
- (7) The affinity support according to any of the above (1) to (6), wherein the support is made of a material selected from the group consisting of an agarose, a sepharose, a dextran, a silica gel, a polyacrylamide, a polystyrene, a polyethylene, a polypropylene, a polyester, a polyacrylonitrile, a (meth)acrylic polymer, a fluorocarbon resin, a metal complex resin, a glass, a metal, and a magnetic substance.
- The affinity support according to the above, wherein the affinity substance is an amino acid or a peptide having 2 to 50 amino acid residues.
- (8) The affinity support according to any of the above (1) to (7), wherein the affinity substance is selected from the group consisting of an immunoglobulin, an immunoglobulin F(ab′) fragment, an immunoglobulin F(ab) fragment, an immunoglobulin Fv fragment, a nucleic acid aptamer, a peptide aptamer, a receptor protein, and a bioactive substance.
- (9) A method of trapping a substance comprising the step of contacting an objective to be trapped with an affinity support comprising a support, a spacer bound to the support and an affinity substance bound to the spacer, so as to bind the objective to be trapped to the affinity substance, wherein each one of the objective to be trapped has a plural of affinity sites and the affinity substance binds to at least two of the affinity sites simultaneously.
- In the present specification, a binding mode in which simultaneous binding of at least two affinity substances to at least two affinity sites (i.e., sites to which affinity substances specifically bind) present in a substance to be trapped is achieved is referred to as cooperative binding. During cooperative binding, it is not required that simultaneous binding to the at least two affinity sites should be always achieved, and for example, there may be a moment when only one of the at least two affinity sites is bound to the affinity substance. That is, cooperative binding is in a state where any one of two or more affinity sites of a substance to be trapped substantially always is bound to an affinity substance so that complete dissociation between the substance to be trapped and the affinity substance is less likely to occur.
- The method for trapping a substance according to the above, further comprising the step of washing a surface of the support, to which the affinity substance bound to the substance to be trapped is bound, at a fluid pressure of 0.1 to 200 MPa.
- The method for trapping a substance according to the above, wherein a maximum dissociation constant KD is 10−7 M.
- (10) The method of trapping a substance according to the above (9), wherein one kind of the affinity substance bound to the spacer exists on the affinity support.
- One specific example of the method according to the above (10) will be described with reference to Example 1.
- (11) The method of trapping a substance according to the above (9), wherein two to five kinds of the affinity substance bound to the spacer exist in the mixed state on the affinity support.
- One specific example of the method according to the above (11) will be described with reference to Example 2.
- The method for trapping a substance according to the above, wherein the spacer has a length of 1 to 100 nm.
- (12) The method of trapping a substance according to any of the above (9) to (11), wherein the spacer comprises an oxyalkylene group.
- (13) The method of trapping the substance according to any of the above (9) to (11), wherein the spacer is selected from the group consisting of a polyalkylene glycol, a polyoxyalkylated polyol, a polyvinyl alcohol, a polyvinyl alkyl ether, a polysaccharide, a biodegradable polymer, and a lipopolymer.
- The method for trapping a substance according to the above, wherein the spacer is branched, the support is bound to a main chain of the spacer, and the affinity substance is bound to a branched chain of the spacer.
- The method for trapping a substance according to the above, wherein an interval between binding positions on the support of the spacers bound to the affinity substances is 1 to 50 angstrom (Å).
- The method for trapping a substance according to the above, wherein the support is made of a material selected from the group consisting of an agarose, a sepharose, a dextran, a silica gel, a polyacrylamide, a polystyrene, a polyethylene, a polypropylene, a polyester, a polyacrylonitrile, a (meth)acrylic polymer, a fluorocarbon resin, a metal complex resin, a glass, a metal, and a magnetic substance.
- The method for trapping a substance according to the above, wherein the affinity substance is an amino acid or a peptide having 2 to 50 amino acid residues.
- The method for trapping a substance according to the above, wherein the affinity substance is selected from the group consisting of an immunoglobulin, an immunoglobulin F(ab′) fragment, an immunoglobulin F(ab) fragment, an immunoglobulin Fv fragment, a nucleic acid aptamer, a peptide aptamer, a receptor protein, and a bioactive substance.
- (14) The method of trapping a substance according to any of the above (9) to (13), wherein each one of the objective to be trapped is one multimer or one aggregate which comprises a plural of molecules, and each of the plural of the affinity sites exists on each of the plural of the molecules.
- (15) The method of trapping a substance according to any of the above (9) and (11) to (13), wherein each one of the objective to be trapped is one molecule.
- (16) The method of trapping a substance according to any of the above (9) to (15), wherein the objective to be trapped is a biological substance or a non-biological substance.
- (17) The method of trapping a substance according to the above (16), wherein the biological substance is selected from the group consisting of a biomarker, a biomarker candidate molecule, and a fragment generated from a biomarker or a biomarker candidate molecule by splicing.
- (18) The method of trapping a substance according to the above (17), wherein the biomarker is related to a disease selected from the group consisting of cancer, brain disease, heart disease, immune disease, hepatic disease, renal disease, and eye disease.
- (19) The method of trapping a substance according to the above (16), wherein the biological substance is a virus or a bacterium.
- (20) The method of trapping a substance according to the above (16), wherein the non-biological substance is an environmentally hazardous substance.
- A method of micro mass spectrometry comprising the steps of:
-
- binding an objective to be trapped to an affinity support by the above method for trapping a substance;
- eluting the objective bound to the affinity support from the affinity support; and
- subjecting the eluted objective to mass spectrometry.
- The present invention provides an affinity support comprising a support, a spacer bound to the support and an affinity substance bound to the spacer, wherein two to five kinds of the affinity substance bound to the spacer exist in a mixed state.
- In some embodiments, the length of the spacer is 1 to 100 nm.
- In some embodiments, the spacer comprises an oxyalkylene group.
- In some embodiments, the spacer is selected from the group consisting of a polyalkylene glycol, a polyoxyalkylated polyol, a polyvinyl alcohol, a polyvinyl alkyl ether, a polysaccharide, a biodegradable polymer, and a lipopolymer.
- In some embodiments, the spacer is branched, the support is bound to a main chain of the spacer, and the affinity substance is bound to a branched chain of the spacer.
- In some embodiments, an interval between binding positions on the support of the spacers bound to the affinity substances is 1 to 50 angstrom (Å).
- In some embodiments, the support is made of a material selected from the group consisting of an agarose, a sepharose, a dextran, a silica gel, a polyacrylamide, a polystyrene, a polyethylene, a polypropylene, a polyester, a polyacrylonitrile, a (meth)acrylic polymer, a fluorocarbon resin, a metal complex resin, a glass, a metal, and a magnetic substance.
- In some embodiments, the affinity substance is selected from the group consisting of an immunoglobulin, an immunoglobulin F(ab′) fragment, an immunoglobulin F(ab) fragment, an immunoglobulin Fv fragment, a nucleic acid aptamer, a peptide aptamer, a receptor protein, and a bioactive substance.
- The present invention provides a method of trapping a substance comprising the step of contacting an objective to be trapped with an affinity support comprising a support, a spacer bound to the support and an affinity substance bound to the spacer, so as to bind the objective to be trapped to the affinity substance, wherein each one of the objective to be trapped has a plural of affinity sites and the affinity substance binds to at least two of the affinity sites simultaneously.
- In some embodiments, one kind of the affinity substance bound to the spacer exists on the affinity support.
- In some embodiments, two to five kinds of the affinity substance bound to the spacer exist in the mixed state on the affinity support.
- In some embodiments, the spacer comprises an oxyalkylene group.
- In some embodiments, the spacer is selected from the group consisting of a polyalkylene glycol, a polyoxyalkylated polyol, a polyvinyl alcohol, a polyvinyl alkyl ether, a polysaccharide, a biodegradable polymer, and a lipopolymer.
- In some embodiments, each one of the objective to be trapped is one multimer or one aggregate which comprises a plural of molecules, and each of the plural of the affinity sites exists on each of the plural of the molecules.
- In some embodiments, each one of the objective to be trapped is one molecule.
- In some embodiments, the objective to be trapped is a biological substance or a non-biological substance.
- In some embodiments, the biological substance is selected from the group consisting of a biomarker, a biomarker candidate molecule, and a fragment generated from a biomarker or a biomarker candidate molecule by splicing.
- In some embodiments, the biomarker is related to a disease selected from the group consisting of cancer, brain disease, heart disease, immune disease, hepatic disease, renal disease, and eye disease.
- In some embodiments, the biological substance is a virus or a bacterium.
- In some embodiments, the non-biological substance is an environmentally hazardous substance.
- According to the present invention, it is possible to provide an affinity support capable of trapping a substance by cooperative binding that is less likely to cause dissociation even when the substance is a molecule other than an antibody, and a trapping method using the same.
- The affinity support according to the present invention achieves a 100 to 100,000 times lower dissociation constant KD than a conventional affinity support. Therefore, the use of the affinity support according to the present invention makes it possible to more efficiently isolate and concentrate a target molecule in a sample (i.e., to bind a target molecule to the affinity support to isolate them from a sample in a concentrated state) as compared to the use of the conventional affinity support. For example, a trapping rate about 5.6 to 8.5 times (molar basis) higher than that of a conventional immunoprecipitation method is achieved, and the sensitivity of analysis of a trapped substance by a mass spectrometer is improved 10-fold. Further, the low dissociation constant KD makes it possible to expand washing conditions and/or reduce non-specific adsorption.
-
FIG. 1 is a schematic diagram showing a method for producing F(ab′)-PEG beads that is one embodiment of an affinity support according to the present invention. -
FIG. 2 is a size exclusion chromatogram of a Ficin digest of 6E10. -
FIG. 3A shows the image of a gel obtained by reducing SDS-PAGE chromatography of the 6E10 digest;FIG. 3B shows the image of a gel obtained by non-reducing SDS-PAGE chromatography of the 6E10 digest. -
FIGS. 4A and 4B are size exclusion chromatograms of a 6E10 F(ab′)2 fraction before (FIG. 4A ) and after (FIG. 4B ) reduction treatment to determine the generation of 6E10 F(ab′) fragments by the reduction treatment. -
FIG. 5 shows the image of a gel obtained by SDS-PAGE chromatography to determine the presence of aggregates of amyloid β (1-42). -
FIG. 6 is a graph showing the amounts of trapped amyloid β (1-42) when reaction solutions containing a fixed amount (100 ng) of amyloid β (1-42) and having different liquid amounts (10, 100, and 1,000 μL) were subjected to various affinity supports (6E10 F(ab′)-PEG24 beads, 6E10 F(ab′)-PEG2 beads, and 6E10 IgG-protein G beads), respectively. -
FIG. 7 shows a comparison of MALDI-TOF MS spectra obtained when different amounts of amyloid β (1-42) were trapped using various affinity supports (6E10 IgG-protein G beads (FIG. 7A ), 6E10 F(ab′)-PEG2 beads (FIG. 7B ), and 6E10 F(ab′)-PEG24 beads (FIG. 7C ) and the MALDI-TOF MS spectrum of pure amyloid β (1-42) (FIG. 7D ). -
FIG. 8 is a size exclusion chromatogram of a LysC digest of 4G8; -
FIG. 9A shows the image of a gel obtained by reducing SDS-PAGE chromatography of the 4G8 digest;FIG. 9B shows the image of a gel obtained by non-reducing SDS-PAGE chromatography of the 4G8 digest. -
FIG. 10 shows a comparison of MALDI-TOF MS spectra obtained when different amounts of amyloid β (1-28) were trapped using various affinity supports (6E10 IgG-protein G beads (FIG. 10A ), 4G8 IgG-protein G beads (FIG. 10B ), 6E10/4G8 IgG-protein G beads (FIG. 10C ), 6E10 F(ab′)-PEG24 beads (FIG. 10D ), 4G8 F(ab′)-PEG24 beads (FIG. 10E ), and 6E10/4G8 F(ab′)-PEG24 beads (FIG. 10F ) and the MALDI-TOF MS spectrum of pure amyloid β (1-28) (FIG. 10G ). -
FIG. 11 shows mass spectra obtained when human plasma in which amyloid β (1-28) was spiked was subjected to an affinity support (6E10 F(ab′)-PEG24 beads). -
FIG. 12 shows a comparison of MALDI-TOF MS spectra obtained when different amounts of amyloid β (1-28) spiked in human plasma were trapped using various affinity supports (6E10 IgG-protein G beads (FIG. 12A ), 4G8 IgG-protein G beads (FIG. 12B ), 6E10/4G8 IgG-protein G beads (FIG. 12C ), 6E10 F(ab′)-PEG24 beads (FIG. 12D ), 4G8 F(ab′)-PEG24 beads (FIG. 12E ), and 6E10/4G8 F(ab′)-PEG24 beads (FIG. 12F ) and the MALDI-TOF MS spectrum of pure amyloid β (1-28) (FIG. 12G ). -
FIG. 13 FIG. 13 shows a mass spectrum obtained when 1 pg (307 amol) of amyloid β (1-28) spiked in human plasma was trapped using an affinity support (6E10/4G8 F(ab′)-PEG24 beads). - An affinity support according to the present invention comprises a support, a spacer bound to the support, and an affinity substance bound to the spacer. The term “bound” includes direct binding and indirect binding.
- The material of the support may be selected from the group consisting of an agarose, a sepharose, a dextran, a silica gel, a polyacrylamide, a polystyrene, a polyethylene, a polypropylene, a polyester, a polyacrylonitrile, a (meth)acrylic polymer, a fluorocarbon resin, a metal complex resin, a glass, a metal, and a magnetic substance.
- The support may have any shape such as a planar shape, a spherical shape, or the like. For example, the support may constitute a chip, a bead, or a flow channel wall in a microdevice for use in separation and/or concentration of a target substance.
- It is preferred that one of the ends of the spacer is bound to the support and the other end is bound to the affinity substance. The spacer can play a role in keeping an appropriate interval between the support and the affinity substance, and in imparting flexibility, or both of flexibility and extensibility to said spacer itself to achieve cooperative binding. The spacer preferably has a chain-like (spacer chain) structure. The presence of the chain-like spacer reduces steric hindrance at the support when an objective to be trapped binds to the affinity substance as compared to when the chain-like spacer is not present. As a result, it is possible to enhance the binding strength between the affinity substance and the objective to be trapped.
- The length of the spacer is, for example, 1 to 100 nm, preferably 1 to 20 nm, more preferably 5 to 10 nm. When the length of the spacer is less than the above lower limit, the spacer is too short and therefore reach of said spacer is not enough to simultaneously bind two or more affinity substances to two or more affinity sites of an objective to be trapped so that cooperative binding is less likely to occur. When the length of the spacer exceeds the above upper limit, the spacer is too long and therefore the degree of freedom of movable range of the affinity substance is contrarily limited so that cooperative binding is less likely to occur.
- The spacer may be, for example, a high molecular weight polymer. The high molecular weight polymer used as the spacer in the present invention usually has a chain-like structure.
- The spacer is preferably non-peptidic. The term “non-peptidic” means having no peptide binding.
- For example, the non-peptidic spacer may contain an oxyalkylene group. An oxyalkylene group-containing group is a divalent group, and may be, for example, one having 2 to 6 carbon atoms. More specifically, an oxyalkylene in the oxyalkylene group-containing group is ethylene oxide or propylene oxide. The oxyalkylene group-containing group is preferably an organic high molecular weight polymer, that is, a polyoxyalkylene group-containing group. The polyoxyalkylene group-containing group is preferably a polyalkylene glycol group obtained by polymerization of an alkylene glycol having 2 to 6 carbon atoms (e.g., polymerization degree: 2 to 40). For example, the polyalkylene glycol group may be selected from the group consisting of polyethylene glycol group (obtained by polymerization of ethylene glycol), and polypropylene glycol group (obtained by polymerization of 1,2-propanediol or 1,3-propanediol).
- In the present invention, particularly, an ethylene glycol group or a polyethylene glycol group having a polymerization degree of 2 to 40, preferably 12 to 36 may be selected as the oxyalkylene group-containing group.
- Alternatively, the non-peptidic spacer may be, for example, an organic high molecular weight polymer selected from the group consisting of a polyoxyalkylated polyol, a polyvinyl alcohol, a polyvinyl alkyl ether, a polysaccharide, a biodegradable polymer, and a lipopolymer. An alkyl group in the polyoxyalkylated polyol or the polyvinyl alkyl ether may have, for example, 1 to 6 carbon atoms, preferably 1 to 3 carbon atoms. Examples of the polysaccharide include a dextran, a mucopolysaccharide, and a chitin. Examples of the mucopolysaccharide include hyaluronic acid. Examples of the biodegradable polymer include PLA (poly(lactic acid)) and PLGA (poly(lactic-glycolic acid)).
- These organic high molecular weight polymers may have a polymerization degree of, for example, 2 to 40, preferably 12 to 36.
- According to one embodiment of the present invention (more specifically, an embodiment in which two or more kinds of the affinity substances are bound to the support in a mixed state), the spacer may be a polypeptide. In the present specification, the term “polypeptide” is used as a generic name for peptides (having, for example, 2 or more and 100 or less amino acid residues) and proteins (having, for example, more than 100 amino acid residues). The polypeptide as the spacer may be a ligand having an affinity for a constant region. Examples of such a ligand include protein A and protein G.
- The spacer used in the present invention may be one containing one of the above-mentioned examples or one containing any two or more selected from the above-mentioned examples.
- The spacer may be straight chain or branched chain. When the spacer is branched, the support is bound to the end of one of chains, that is, a main chain, and the affinity substance is bound to the end of the other chain, that is, a branched chain. The number of branched chains is not particularly limited, and may be, for example, 2 to 10. When the spacer is branched, the density of the affinity substance on the affinity support can be increased as compared to when the spacer is straight chain.
- The affinity substance may be either a guest substance or a host substance that can generally construct a molecular recognition system and can interact by non-covalent bonding. The affinity substance is preferably a host substance.
- In the present invention, interaction in molecular recognition means that the affinity substance recognizes and non-covalently interacts with an affinity site of an objective to be trapped, and may be, for example, specific binding with such an affinity that an association rate constant ka (unit: 1/Ms) of at least 103 or 104, for example, 103 to 105 or 104 to 105 is achieved. The number of specific binding sites per one affinity substance may be one or two or more (e.g., five or less).
- The affinity substance may or may not have a naturally-derived structure.
- Examples of the affinity substance include amino acids and polypeptides. More specifically, the affinity substance may be an amino acid or a polypeptide having 2 to 50 amino acid residues.
- Another example of the affinity substance is one selected from the group consisting of an immunoglobulin and an immunoglobulin fragment. The immunoglobulin fragment is not particularly limited as long as it has the ability to bind to antigen, and can be selected from, for example, the group consisting of F(ab′)2, F(ab′), Fab, Fd, Fv, L-chain, and H-chain. Among them, from the viewpoint of reducing non-specific adsorption, the immunoglobulin fragment is preferably selected from the group consisting of an immunoglobulin F(ab′) fragment, an immunoglobulin F(ab) fragment, and a Fv fragment which have no Fc region. Examples of the immunoglobulin include IgG1, IgG2, IgG3, IgG4, and the like. The immunoglobulin may be derived from any animal, but is particularly derived from a human.
- Another example of the affinity substance is one selected from the group consisting of a nucleic acid aptamer, a peptide aptamer, a receptor protein, and a bioactive substance. Examples of the bioactive substance include cytokine, hormones, and neurotransmitters.
- The interval between binding positions on the support of the spacers bound to the affinity substances is not particularly limited, and can be appropriately determined by those skilled in the art so that the affinity substances are preferably present as dense as possible. More specifically, the interval between the affinity substance-binding positions may vary depending on, for example, the size of the affinity substance, but is, for example, 1 to 1,000 angstrom (Å), preferably 1 to 100 angstrom, more preferably 1 to 50 angstrom, even more preferably 1.5 to 30 angstrom. The above lower limit substantially corresponds to the physical limit of the interval between adjacent affinity substances. On the other hand, if the interval between the affinity substance-binding positions exceeds the above upper limit, the affinity substances are sparse and therefore cooperative binding is less likely to occur.
- According to one embodiment of the present invention, one kind of the affinity substance bound to the support via the spacer is present on the support (more specifically, in a specific region on the support).
- According to another embodiment of the present invention, two or more kinds of the affinity substances bound to the support via the spacer are present on the support (more specifically, in a specific region on the support). The number of kinds of the affinity substances used in this embodiment is two or more, but is smaller than, for example, the number of kinds of antibodies constituting a common polyclonal antibody. The amounts of two to five kinds of the affinity substances are preferably the same or close to each other. More specifically, two to five kinds of the affinity substances can be used in such a manner that the difference in amount between arbitrary two kinds of the affinity substances selected from the two to five kinds of affinity substances is within 20%, preferably within 10%, more preferably within 5% (molar basis). Further, in this embodiment, different kinds of the affinity substances are present on the same support in a mixed state. The embodiment in which different kinds of the affinity substances are present on the same support in a mixed state is clearly distinguished from an embodiment in which different kinds of the affinity substances are bound in a state where they can be differentiated from each other (e.g., a microarray).
- Treatment may be performed on the specific region on the support depending on the kind of affinity substance bound thereto or the combination of different kinds of the affinity substances bound thereto. Two or more regions may be provided on the same support in such a manner that the kind of affinity substance bound thereto or the combination of different kinds of the affinity substances bound thereto varies from region to region. In this case, different treatments can be performed on the different regions on the same support.
- The affinity support according to the present invention can be prepared by binding a support having a binding functional group on surface of said support to an affinity substance having a binding functional group via a spacer substance having both a binding functional group corresponding to the binding functional group of the support and a binding functional group corresponding to the binding functional group of the affinity substance simultaneously (i.e., a bifunctional spacer substance) or successively (i.e., a monofunctional spacer substance).
- The binding functional group of each of the components, namely, the support, the spacer substance, and the affinity substance, may be selected from the group consisting of covalent binding functional group, ion binding functional group, and hydrogen binding functional group. Particularly, a covalent binding functional group is preferred.
- A combination of binding functional groups of the components corresponding to each other can be easily determined by those skilled in the art so that binding selected from the group consisting of covalent binding, ion binding, and hydrogen binding, preferably covalent binding can be achieved.
- For example, when the binding functional group of one of the components is an amino group, examples of the binding functional group of the corresponding other component include a carboxyl group, an active ester group (e.g., an N-hydroxysuccinimide (NHS) ester group, and an N-hydroxysulfosuccinimide (Sulfo-NHS) ester group), an epoxy group, an aldehyde group, an isocyanato group, an isothiocyanato group, and the like. When the binding functional group of one of the components is a thiol group, examples of the binding functional group of the corresponding other component include a maleimide group, a pyridyldisulfide group, a vinylsulfone group, a bromoacetyl group, and the like. When the binding functional group of one of the components is a hydroxyl group, examples of the binding functional group of the corresponding other component include an epoxy group, a silyl chloride group, and the like.
- The support having a binding functional group on a surface of said support can be prepared by a self-organizing surface method in which molecules having a binding functional group are arranged on the surface of a support; a method in which the surface of a support is coated with a substance having a binding functional group; a method in which a substance having a binding functional group and a functional group that can covalently bind to a support is covalently bound to the surface of the support; or the like. Among these methods, the support having a binding functional group on a surface of said support is preferably prepared by the method based on covalent binding. Among the above-mentioned examples of the binding functional group, an amino group is particularly preferred as the binding functional group of the support.
- The density of the binding functional group on the support is, for example, 0.001 to 0.5 mmol/m2, preferably 0.01 to 0.1 mmol/m2.
- Each of the binding functional groups of the spacer substance may be one that is naturally present in a biomolecule, one that an organic high molecular weight polymer previously has, or one that is artificially produced by decomposition, synthesis, or modification. A method for producing the binding functional group can be easily selected by those skilled in the art. The binding functional group of the spacer substance corresponding to the binding functional group of the support and the binding functional group of the spacer substance corresponding to the binding functional group of the affinity substance may be the same or different from each other. Among the above-mentioned examples of the binding functional group, a particularly preferred example of a combination of the binding functional groups of the spacer substance is a combination of an active ester group and a maleimide group.
- The binding functional group of the affinity substance may be one that is naturally present in a naturally-derived structure or one that is artificially produced by decomposition, synthesis, or modification. That is, the affinity substance having a binding functional group is prepared by a method appropriately selected by those skilled in the art from, for example, isolation from the living body of an organism, decomposition of an isolate from a living body, synthesis by genetic engineering, biochemical synthesis and modification, and organic chemical synthesis and modification. Among the above-mentioned examples of the binding functional group, a thiol group is particularly preferred as the binding functional group of the affinity substance. For example, when the affinity substance is an immunoglobulin fragment, the immunoglobulin fragment can be prepared by digestion using an enzyme (e.g., papain, pepsin, ficin, or the like), and/or by cleavage of disulfide bonds using a reducing agent.
- The order in which the respective components are bound to one another is not particularly limited. Therefore, binding between the spacer substance and the affinity substance may be achieved after the support and the spacer substance are bound to each other, or binding between the spacer substance and the support may be achieved after the affinity substance and the spacer substance are bound to each other. When the respective components are successively bound to one another in this way, the spacer substance may be either monofunctional or bifunctional. When a monofunctional spacer substance is used as the spacer substance, the respective components may be bound to one another by, for example, binding the support having a binding functional group to the monofunctional spacer substance having a binding functional group corresponding to the binding functional group of the support, and then producing a binding functional group of the spacer substance corresponding to a binding functional group of the affinity substance, and then binding the spacer substance to the affinity substance via the produced binding functional group.
- On the other hand, the respective components may be bound to one another simultaneously by using a bifunctional spacer substance as the spacer substance and subjecting the support, the bifunctional spacer substance, and the affinity substance to the same reaction system.
- Further, the respective components are used in such amounts that the affinity substance is bound as dense as possible. More specifically, the spacer substance can be used in an
amount 10 to 5,000 times (molar basis) the amount of the binding functional group present in a region on the support where the affinity substance is to be bound, and the affinity substance can be used in an amount 0.1 to 10 times (molar basis) the amount of the binding functional group present in a region on the support where the affinity substance is to be bound. - The affinity support according to the present invention can be used by subjecting said affinity support to a molecular recognition system selected by those skilled in the art depending on the affinity substance bound thereto. More specifically, a sample containing a substance to be trapped is brought into contact with the affinity support to bind the substance to be trapped contained in the sample to the affinity substance on the affinity support.
- According to one embodiment of the present invention, one objective to be trapped is a single molecule. According to another embodiment of the present invention, one objective to be trapped is one dimer or higher-order multimer composed of two or more molecules or one aggregate.
- In one objective to be trapped, two or more affinity sites, that is, sites that specifically bind to the affinity substance(s) are present. The use of the affinity support according to the present invention makes it possible to simultaneously bind at least two affinity substances to at least two of the two or more affinity sites present in one objective to be trapped (i.e., to achieve cooperative binding). During cooperative binding, it is not required that simultaneous binding to the at least two affinity sites should be always achieved. For example, there may be a moment when only one of the at least two affinity sites is bound to the affinity substance. That is, cooperative binding allows any one of the two or more affinity sites of the substance to be trapped to be always bound to the affinity substance, which makes it easy to keep a state where the substance to be trapped is trapped by the affinity substance. In other words, complete dissociation between the substance to be trapped and the affinity substance is less likely to occur.
- According to the present invention, as described above in 1-3, the association rate constant ka (unit: 1/Ms) for binding of the affinity substance is comparable to the association rate constant ka of a conventional common molecular recognition system. On the other hand, the dissociation rate constant kd (unit: 1/s) for binding of the affinity substance is lower than that for the conventional common molecular recognition system. Therefore, according to the present invention, the dissociation constant KD (unit: M) for binding of the affinity substance is smaller than that for the conventional common molecular recognition system, and is, for example, 10−7, 10−8, 10−9, 10−10, 10−11, or 10−12 at the maximum and may be, for example, 10−13 to 10−7.
- For example, when one objective to be trapped is a single molecule, two or more affinity sites are present in the single molecule. In this case, the two or more affinity sites present in the single molecule are generally different from each other. Therefore, two or more different kinds of the affinity substances need to be bound to the affinity support so that the affinity substances can bind to at least two affinity sites simultaneously.
- When one objective to be trapped is composed of two or more molecules, at least one affinity site needs to be present in each of the molecules. In this case, two or more molecules constituting one objective to be trapped are generally the same, and therefore have the same at least one affinity site. Therefore, one kind of the affinity substance is bound to the affinity support. However, in this case, the possibility that two or more kinds of the affinity substances are bound to the affinity support is not particularly excluded.
- An objective to be trapped by the affinity support according to the present invention can be easily determined by those skilled in the art depending on the kind of affinity substance bound thereto or the combination of different kinds of the affinity substances bound thereto.
- The objective to be trapped may or may not have a naturally-derived structure.
- Specific examples of the objective to be trapped include biological substances, especially polypeptides, sugar chains, nucleic acids, and conjugates of two or more of them (e.g., conjugates obtained by arbitrarily combining two or more of them such as glycopeptides and peptide nucleic acids). These biological substances may have a molecular weight of, for example, 200 to 1,000,000, preferably 1,000 to 200,000.
- A more specific example of the objective to be trapped is a biological substance selected from the group consisting of a biomarker, a biomarker candidate molecule, and a fragment generated from a biomarker or a biomarker candidate molecule by splicing. Further, the biomarker may be one related to a disease selected from the group consisting of cancer, brain disease (e.g., Alzheimer's disease), heart disease, immune disease, hepatic disease, renal disease, and eye disease. When the objective to be trapped is such a biological substance, initial diagnosis of diseases, follow-up of diseases, and/or evaluation of sensitivity of chemotherapy for diseases can be performed by the present invention.
- Another more specific example of the objective to be trapped is a virus. In this case, the affinity support can trap the surface antigen of a virus. The affinity support according to one embodiment of the present invention having two to five kinds of the affinity substances bound thereto can easily respond to variations of a virus that may be created by varying its surface antigen.
- Another more specific example of the objective to be trapped is a cell selected from the group consisting of bacterial cell, animal cell, and plant cell. In this case, the affinity support can trap, for example, a receptor constituting a dimer or higher-order multimer such as a vascular endothelial cell growth factor receptor (VEGFR), an epidermal growth factor receptor (EGFR), or a tumor necrosis factor receptor (TNFR).
- Another specific example of the objective to be trapped is a non-biological substance, especially an environmentally hazardous substance. Examples of the environmentally hazardous substance include compounds such as dioxin, estrogen, polychlorinated biphenyl, and the like. Other than these compounds, the non-biological substance may be a low molecular weight compound having a molecular weight of 100 to 1,000, preferably 200 to 700.
- Another specific example of the objective to be trapped is a multimer or aggregate of drug molecules. The present invention is useful also when association or aggregation of drug molecules becomes a problem during drug preparation. In most cases, drug molecules having the risk of causing such a problem are polypeptide drug molecules. Therefore, examples of such drug molecules include polypeptide drug molecules, and specific examples of the polypeptide drug molecules include insulin, parathyroid hormone and the like.
- A sample to be subjected to the affinity support is not particularly limited as long as it contains the above-described objective to be trapped. The sample is usually prepared in a liquid state. The objective to be trapped contained in the sample does not always need to be purified. When the objective to be trapped is purified, the degree of purification is not an issue. According to the present invention, from the viewpoint of microanalysis of the objective to be trapped, there is a case where the degree of treatment such as purification performed on the objective to be trapped contained in the sample is preferably low.
- Examples of the sample to be subjected to the affinity support include biological samples prepared from cells, tissues, body fluids, secretions, and excretions of organisms. A typical biological sample prepared from a body fluid is a blood-derived sample. Examples of the blood-derived sample include whole blood, blood plasma, and blood serum. An example of operation that can be performed when a blood-derived sample is prepared from a body fluid is removal of blood cells (more specifically, red blood cells, white blood cells, and/or blood platelets) by centrifugation after addition of an anticoagulant agent (e.g., ethylenediamine tetra-acetic acid, citric acid, or heparin) to blood. Another example of operation that can be performed during preparation of a blood-derived sample is removal of a blood coagulation factor and blood cells after blood coagulation and centrifugation. It is well known that blood undergoes a dynamic change in its components due to the occurrence of disease. Therefore, the blood-derived sample can be used for early diagnosis, follow-up, and/or follow-up after treatment of various diseases by using molecules whose blood levels vary as biomarkers. Further, novel marker molecules in blood have the potential to achieve early diagnosis and high-accuracy diagnosis in the future. Therefore, the blood-derived sample can also be used to search novel marker molecules in blood for the purpose of developing a novel diagnostic method.
- By subjecting such a biological sample to the affinity support, it is possible to trap a target substance contained in the sample and examine the trapped target substance.
- Another example of the sample to be subjected to the affinity support is an environmental sample prepared from an environmental substance. Examples of the environmental substance include soil, strata, water, air, and the like. An example of operation that can be performed when an environmental sample is prepared from an environmental substance is extraction using an organic solvent (e.g., acetone or toluene).
- By subjecting such an environmental sample to the affinity support, it is possible to trap a target substance contained in the sample and examine the trapped target substance.
- Another example of the sample to be subjected to the affinity support is an unpurified drug sample. By subjecting such a drug sample to the affinity support, it is possible to remove unnecessary substances (multimers and aggregates of drug molecules) contained in the sample to obtain a purified drug.
- The concentration of the objective to be trapped contained in the sample may be, for example, 1 to 1012 amol/mL, preferably 100 to 10′ amol/mL. The sample can be subjected to the affinity support in such a manner that the amount of the objective to be trapped is 0.1 to 500 pmol, preferably 1 to 100 pmol per 1 cm2 of the surface of the support.
- After the affinity substance bound to the support and the objective to be trapped are bound to each other, the surface of the support may be subjected to a washing process. The washing process can be performed by subjecting the surface of the support to a fluid pressure of 0.01 to 500 MPa, preferably 0.05 to 300 MPa, more preferably 0.1 to 200 MPa to remove unnecessary components. If the fluid pressure is less than the above lower limit, a desired washing effect is less likely to be obtained. If the fluid pressure exceeds the above upper limit, there is a fear that binding between the affinity substance and the trapped objective is cleaved. The affinity support according to the present invention can hold an objective to be trapped by cooperative binding, and therefore can be washed under higher pressure conditions as compared to when a conventional affinity support is used. Such expansion of washing conditions improves the removal efficiency of substances non-specifically adsorbed to the affinity support, which as a result contributes to an improvement in the sensitivity of analysis of the trapped objective.
- It is to be noted that a specific washing method is not particularly limited. For example, when having a spherical shape, the affinity support can be washed by vigorously stirring said affinity support in a washing liquid. When having a planar shape, the affinity support can be washed by spraying said affinity support with a high-pressure washing liquid discharged from a spray nozzle. More specifically, in order to subject the specific region on the planar-shaped support to high-pressure washing, a spray nozzle having an inner diameter corresponding to the area of the specific region can be used. This nozzle is constituted from, for example, a double pipe, and an inner pipe can function only as an injection pipe for spraying the surface of the support with a washing liquid, and an outer pipe can function only as a drain pipe for sucking the washing liquid sprayed onto the surface of the support.
- The trapped objective can be analyzed by an appropriate detection system in a state where said trapped objective remains bound to the affinity support, or said trapped objective is collected by elution from the affinity support (i.e., by releasing the trapped objective by cleaving the binding between the trapped objective and the affinity substance). The elution of the trapped objective from the affinity support can be performed by subjecting the affinity support bound to the trapped objective to an eluate that can be easily selected by those skilled in the art depending on the combination of the trapped objective and the affinity substance.
- In the present invention, as an example of the detection system, one based on radioactive assay, enzyme activity assay, fluorescence intensity assay, or emission intensity assay can be used.
- For example, when a molecular recognition system to which the affinity support is subjected is an immune system, adetection system based on any solid phase immunoassay may be selected. For example, a detection system based on radioimmunoassay (RIA), enzyme immunoassay (EIA, ELISA), fluorescence immunoassay (FIA), chemiluminescent immunoassay (CLIA), or the like is selected. A label (selected from the group consisting of radioisotope, enzyme, fluorescent substance, and chemiluminescent substance) can be suitably and previously bound to the affinity substance and/or the objective to be trapped by those skilled in the art depending on the kind of detection system used.
- When a molecular recognition system to which the affinity support is subjected is an aptamer-receptor protein system, the detection system used can be based on the detecting method used in the above-described immune system. The use of the aptamer-receptor protein system is preferred because the aptamer-receptor protein system is superior to the above-described immune system in specific binding ability and ease of aptamer preparation.
- In the present invention, as a preferred example of the detection system other than the above-described detection system, an optical detection system based on surface Plasmon resonance (SPR), sum frequency generation (SFG), local Plasmon resonance (LPR), ellipsometry, or the like is used. Unlike the above-described detection system, such an optical detection system does not require a label.
- In the present invention, as another preferred example of the detection system other than the above-described detection system, a detection system based on mass spectrometry is used. In this case, Matrix Assisted Laser Desorption/Ionization (MALDI) mass spectrometry is preferably used as a method of mass spectrometry. For example, a MALDI-TOF (Matrix Assisted Laser Desorption/Ionization-Time of Flight) mass spectrometer, a MALDI-IT (Matrix Assisted Laser Desorption/Ionization-Ion Trap) mass spectrometer, a MALDI-IT-TOF (Matrix Assisted Laser Desorption/Ionization-Ion Trap-Time of Flight) mass spectrometer, a MALDI-FTICR (Matrix Assisted Laser Desorption/Ionization-Fourier Transform Ion Cyclotron Resonance) mass spectrometer, or the like can be used.
- A matrix and a matrix solvent can be easily determined by those skilled in the art depending on the kind of objective to be analyzed (i.e., depending on the kind of objective trapped by the affinity support).
- As the matrix, for example, α-cyano-4-hydroxycinnamic acid, 2,5-dihydroxybenzoic acid, sinapic acid, 3-aminoquinoline, or the like can be used.
- The matrix solvent to be used can be selected from, for example, the group consisting of acetonitrile (ACN), trifluoroacetic acid (TFA), methanol, ethanol, and water. More specifically, an aqueous ACN-TFA solution, an aqueous ACN solution, an aqueous methanol-TFA solution, an aqueous methanol solution, an aqueous ethanol-TFA solution, an ethanol solution, or the like can be used. The concentration of ACN in the aqueous ACN-TFA solution may be, for example, 10 to 90 vol % and the concentration of TFA may be, for example, 0.05 to 1 vol %, preferably 0.05 to 0.1 vol %.
- The concentration of the matrix may be, for example, 0.1 to 50 mg/mL, preferably 0.3 to 20 mg/mL, more preferably 0.5 to 20 mg/mL.
- When a detection system based on MALDI mass spectrometry is used, a matrix additive (co-matrix) is preferably used in combination with the matrix. The matrix additive can be appropriately selected by those skilled in the art depending on the kind of objective to be analyzed and/or the kind of matrix to be used. For example, as the matrix additive, a phosphonic acid group-containing compound can be used. Specific examples of a compound containing one phosphonic acid group include phosphonic acid, methylphosphonic aid, phenylphosphonic acid, 1-naphthylmethylphosphonic acid, and the like. Specific examples of a compound containing two or more phosphonic acid groups include methylenediphosphonic acid, ethylenediphosphonic acid, ethane-1-hydroxy-1,1-diphosphonic acid, nitrilotriphosphonic acid, ethylenediaminetetraphosphonic acid, and the like. Among the above-mentioned phosphonic acid group-containing compounds, those containing two or more phosphonic acid groups, preferably 2 to 4 phosphonic acid groups in one molecule are preferred.
- The use of the phosphonic acid group-containing compound is useful, for example, when an oxyalkylene group-containing group is used as the spacer. The oxyalkylene group-containing group has the property of incorporating positively-charged metal ions around its oxygen atoms, but the metal ions adversely affect the background in mass spectrometry. The use of the phosphonic acid group-containing compound has the effect of reducing such an adverse effect.
- It is to be noted that other than the above-mentioned matrix additive, a more common additive selected from, for example, the group consisting of ammonium salt and organic base may be used.
- The matrix additive can be prepared as a 0.1 to 10 w/v %, preferably 0.2 to 4 w/v % aqueous solution or matrix solvent solution. A matrix additive solution and a matrix solution can be mixed in a volume ratio of, for example, 1:100 to 100:1, preferably 1:10 to 10:1.
- Hereinbelow, the present invention will be described more specifically with reference to examples, but is not limited to the following examples. In the following description, the amount of a substance expressed as “%” is based on weight when the substance is solid and on volume when the substance is liquid unless otherwise specified.
- A procedure for preparing 6E10 F(ab′)-PEGn beads is schematically shown in
FIG. 1 . - First, antibody F(ab′) fragments were prepared. More specifically, 250 μg of anti-amyloid β antibody (6E10) whose epitope includes residues 3 to 8 of amyloid β was digested with 1,250 μL of Ficin agarose beads (Thermo) (33% slurry), and a Ficin digest was separated by size exclusion chromatography.
FIG. 2 shows the result of separation of the Ficin digest of 6E10 by size exclusion chromatography.FIG. 3A shows the image of a gel obtained by reducing SDS-PAGE chromatography of the fractionated digest of 6E10, andFIG. 3B shows the image of a gel obtained by non-reducing SDS-PAGE chromatography of the fractionated digest of 6E10. In the nature of F(ab′)2, a band appears at about 100 kDa under non-reducing conditions, and at 25 kDa under reducing conditions due to the cleavage of the disulfide bonds between the H and L chains. Successful purification of 6E10 F(ab′)2 was confirmed by recognizing fractions 24-29 showing a band at 25 kDa under reducing conditions (FIG. 3A ) and at about 100 kDa under non-reducing conditions (FIG. 3B ). These fractions 24-29 were collected as a F(ab′)2 fraction. This 6E10 F(ab′)2 fraction was reduced with a 30 mM aqueous 2-mercaptoethylamine (MEA) solution.FIG. 4 shows size exclusion chromatograms of the F(ab′)2 fraction before reduction treatment (FIG. 4A ) and after reduction treatment (FIG. 4B ). It was confirmed fromFIG. 4 that 6E10 F(ab′) was generated by reduction of the 6E10 F(ab′)2 fraction. - Then, 5 μL of amino magnetic beads (Dynabeads M-270 Amine: Invitrogen) (33% slurry) was prepared, and amino groups on the surfaces of the beads were reacted with NHS groups of SM(PEG)n (n=2, 24) at room temperature for 30 minutes to covalently bind PEG to the beads (
FIG. 1 shows a case where n=24). Then, F(ab′) was reacted with maleimide groups of SM(PEG)n bound to the magnetic beads at room temperature for 30 minutes to covalently bind F(ab′) to SM(PEG)n. - For a control experiment, IgG-protein G beads were prepared by affinity binding of 0.75 μg of 6E10 IgG to 5 μL of protein G magnetic beads (Dynabeads Protein G: Invitrogen) (33% slurry).
- As an antigen, amyloid β (1-42) was used. It is known that C-terminus of amyloid β (1-42) aggregates to form multimers. Therefore, one amyloid β (1-42) aggregate has two or more epitopes for 6E10, and therefore can be used as a material suitable for evaluation of the binding strength of cooperative binding. It is to be noted that the aggregation of amyloid β (1-42) used in this example was confirmed by SDS-PAGE. Amyloid β (1-42) whose concentration was 3 to 100 μg/mL was separated by SDS-PAGE, and the gel was stained with silver. The image of the gel is shown in
FIG. 5 . As shown inFIG. 5 , monomers, trimers, and tetramers of amyloid β (1-42) were detected. - The three kinds of beads, 6E10 F(ab′)-PEGn beads (n=2, 24) and 6E10 IgG-protein G beads were washed three times with TBS (10 mM Tris-HCl, 150 mM NaCl, pH 7.4)-1% n-octyl-β-D-thioglycoside (OTG) respectively, and then the beads of each kind were reacted with amyloid β (1-42) at room temperature for 1 hour while they were mixed by inversion. Then, the resultant beads were washed with TBS-1% OTG three times and with H2O once. Then, the beads were subjected to elution with 5 μL of 3 mM HCl twice to obtain an each eluate. In this way, isolation and concentration of an objective to be trapped were performed. The eluate was analyzed by sandwich ELISA and MALDI-TOF MS in the following manner.
- A solution in which anti-amyloid β antibody (4G8) was dissolved at 0.5 μg/mL in a carbonate buffer (15 mM Na2CO3, 35 mM NaHCO3, pH 9.6) was placed in wells of a 96-well plate in an amount of 100 μL/well and allowed to stand at 4° C. overnight. Then, the antibody solution placed in the wells was removed, and a 20% blocking buffer (Nacalai Tesque) was placed in the wells in an amount of 200 μL/well and allowed to stand at room temperature for 2 hours. The wells were washed with 300 μL/well of a washing buffer (10 mM Na2HPO4, 1.76 mM KH2PO4, 137 mM NaCl, 2.7 mM KCl, 0.1% Tween) three times.
- A solution in which amyloid β (1-42) was dissolved at a known concentration in a reaction buffer (10 mM Na2HPO4, 1.76 mM KH2PO4, 137 mM NaCl, 2.7 mM KCl, 0.1% Tween, 5% blocking buffer (Nacalai Tesque)), and a sample obtained by diluting the eluate obtained in the above (4) with the above-described reaction buffer 100-fold were placed in the wells separately in an amount of 100 μL/well and shaken at room temperature for 1 hour. The wells were washed with 300 μL/well of the washing buffer five times, and then a 0.1 μg/mL HPR-labeled anti-amyloid β antibody (6E10-HPR) was placed in the wells in an amount of 100 μL/well and shaken at room temperature for 1 hour. The wells were washed with 300 μL/well of a washing buffer (PBS-0.1% Tween) five times, and then TMB was placed in the wells in an amount of 100 μL/well and shaken at room temperature for 15 minutes. After 1N H2SO4 was added to the wells in an amount of 100 μL/well, absorbance (450 nm/650 nm) of the wells was measured using a plate reader.
- On a MALDI plate, 1 μL of the eluate obtained in the above (4) and 1 μL of a solution of α-cyano-4-hydroxycinnamic acid (CHCA) in which CHCA was dissolved at 0.5 mg/mL in a 50% aqueous acetonitrile solution containing 0.1% trifluoroacetic acid were dropped and mixed to obtain a sample. The sample was analyzed using AXIMA performance (Shimadzu Corporation) in linear mode. In order to allow a comparison to be made among samples, all the samples were analyzed in raster mode under fixed conditions where the number of profiles was 500, the number of shots per profile was 5, and the number of laser shots was 100 points. A criterion for peak detection was S/N≥3.
- Isolation and concentration of amyloid β (1-42) were performed using the different kinds of beads (i.e, 6E10 F(ab′)-PEG24 beads, 6E10 F(ab′)-PEG2 beads, and 6E10 IgG-protein G beads) under conditions where the amount of amyloid β (1-42) as an antigen was set to a fixed value of 100 ng, the number of the beads of each kind was set to a fixed value of 107, and the liquid amounts of a reaction solution were set to 10, 100, and 1,000 μL (i.e., variations of concentration levels of antibody and antigen were 1×, 10×, and 100×). The amount of the antigen trapped for isolation and concentration was measured by ELISA. A graph representing the amount of trapped amyloid β (1-42) is shown in
FIG. 6 . The amount of the antigen trapped by the 6E10 F(ab′)-PEG24 beads was 5.9 to 8.5 times larger than that trapped by the 6E10 IgG-protein G beads, and the amount of the antigen trapped by the 6E10 F(ab′)-PEG2 beads was 5.6 to 6.9 times larger than that trapped by the 6E10 IgG-protein G beads. - All the three kinds of beads showed a tendency that the amount of the trapped antigen was reduced as the amount of the reaction solution was increased. However, the rate of the reduction was lower when the 6E10 F(ab′)-PEG24 beads were used than when the 6E10 F(ab′)-PEG2 beads were used. When the amount of the reaction solution was 1,000 μL, the amount of the trapped antigen was largest when the 6E10 F(ab′)-PEG24 beads were used. Here, the rate of binding of the antigen to the antibody varies depending on the respective molar concentrations of the antibody, and the antigen and the association rate constant (ka) and dissociation rate constant (kd) of the antibody. According to the result of SPR described in the Non-Patent Document 2 (Proceedings of the Japan Academy, Ser. B, Physical and Biological Sciences 2011; 87(9): 603-16), there is no difference in the association rate constant (ka) of an antigen-antibody reaction between when cooperative binding occurs and when cooperative binding does not occur, but the dissociation rate constant (kd) of the antigen-antibody reaction is lower when cooperative binding occurs than when cooperative binding does not occur.
- From the result that the amount of the trapped antigen was larger when the F(ab′)-PEG24 beads were used than when the F(ab′)-PEG2 beads were used, it is considered that preferred cooperative binding (i.e., binding with a lower kd) occurred when the F(ab′)-PEG24 beads bind to the antigen. This indicates that the F(ab′)-PEG24 beads can be used as a more effective tool for trapping molecules whose concentration in a biological sample is lower.
- An experiment was performed to verify that the amount of antigen required for detection by a mass spectrometer is smaller when the method according to the present invention is used than when a conventional immunoprecipitation method is used (i.e., than when the 6E10 IgG-protein G beads are used).
FIG. 7 shows the MALDI-TOF MS spectra of amyloid β (1-42) eluates obtained when the 6E10 IgG-protein G beads were used (FIG. 7A ), the MALDI-TOF MS spectra of amyloid β (1-42) eluates obtained when the 6E10 F(ab′)-PEG2 beads were used (FIG. 7B ), the MALDI-TOF MS spectra of amyloid β (1-42) eluates obtained when the 6E10 F(ab′)-PEG24 beads were used (FIG. 7C ), and the MALDI-TOF MS spectra of pure amyloid β (1-42) (directly) spotted onto a MALDI plate without being trapped by beads (FIG. 7D ). The detection limits of amyloid β (1-42) in all the cases are shown in Table 1. -
TABLE 1 Detection Limit (S/N ≥ 3) 6E10 IgG- Directly protein G 6E10 F(ab′)-PEG2 6E10 F(ab′)-PEG24 Spotting 100 pg 25 pg 25 pg 25 pg (22.2 fmol) (5.54 fmol) (5.54 fmol) (5.54 fmol) - When a conventional immunoprecipitation method was used, that is, when the 6E10 IgG-protein G beads were used, the amount of amyloid β (1-42) required for detection by MALDI-TOF MS was 100 pg. On the other hand, when the method according to the present invention was used, that is, when the 6E10 F(ab′)-PEG24 beads or the 6E10 F(ab′)-PEG2 beads were used, the amount of amyloid β (1-42) required for detection by MALDI-TOF MS was only 25 pg. This indicates that the amount of antigen required for detection by a mass spectrometer is smaller when the method according to the present invention is used than when the conventional immunoprecipitation method is used. In addition, the detection level achieved by the method according to the present invention was equivalent to the detection limit achieved by directly spotting amyloid β (1-42) onto a MALDI plate. That is, the method according to the present invention makes it possible to collect amyloid β (1-42) from a sample at a rate nearly 100%.
- When molecules forming homomultimers such as amyloid β (1-42) are an objective to be trapped, the amount of the trapped objective can be increased when the 6E10 F(ab′)-PEGn beads of Example 1 derived from one kind of antibody are used as compared to when the 6E10 IgG-protein G beads are used.
- On the other hand, in this example, beads having two kinds of F(ab′) fragments were prepared based on the premise that, when a single molecule of an antigen is an objective to be trapped, at least two kinds of antibody-derived F(ab′) fragments that recognize two or more sites in the antigen single molecule are necessary to increase the amount of the trapped antigen.
- One of two kinds of F(ab′) fragments was prepared in the same manner as in Example 1 from anti-amyloid β antibody 6E10 whose epitope includes 3-8 residues of amyloid R, and the other was prepared from anti-amyloid β antibody 4G8 whose epitope includes 18-22 residues of amyloid β. The 4G8 antibody is an IgG2b, and therefore F(ab′)2 cannot be obtained by Ficin or Pepsin. For this reason, F(ab′)2 was obtained by lysyl-end peptidase (LysC). More specifically, 100 μg of 4G8 was digested with 500 ng of LysC for 2.5 hours, and then a LysC digest was separated by size exclusion chromatography.
-
FIG. 8 shows the result of separation of the LysC digest of 4G8 by size exclusion chromatography. Further,FIG. 9 shows the image of a gel obtained by reducing SDS-PAGE chromatography of the fractionated digest of 4G8 (FIG. 9A ) and the image of a gel obtained by non-reducing SDS-PAGE chromatography of the fractionated digest of 4G8 (FIG. 9B ). The fractions 16-29 showing a band at about 150 kDa under non-reducing conditions and at 25 kDa under reducing conditions were collected as a 4G8 F(ab′)2 fraction. The 4G8 F(ab′)2 fraction was reduced to obtain 4G8 F(ab′). - Beads to each of which two kinds of F(ab′) fragments were bound via PEG, that is, 6E10/4G8 F(ab′)-PEG24 beads were prepared in the same manner as in (1) in Example 1 except that the 4G8 F(ab′) fraction and the 6E10 F(ab′) fraction obtained in (1) in Example 1 were used in 1:1 (molar ratio) as the F(ab′) fraction.
- (1-2) Preparation of 6E10 F(ab′)-PEG24 Beads and 4G8 F(ab′)-PEG24 Beads
- For reference experiments, the same 6E10 F(ab′)-PEG24 beads as used in Example 1 were prepared, and 4G8 F(ab′)-PEG24 beads were prepared in the same manner as in (1) in Example 1 except that the 4G8 F(ab′) fraction was used as the F(ab′) fraction.
- Protein G beads to each of which two kinds of antibodies were bound, that is, 6E10/4G8 IgG-protein G beads were prepared in the same manner as in (2) in Example 1 except that the 4G8 IgG and the 6E10 IgG were used in 1:1 (molar ratio).
- For control experiments, the same 6E10 IgG-protein G beads as used in Example 1 were prepared, and 4G8 IgG-protein G beads were prepared in the same manner as in (2) in Example 1 except that 4G8 IgG was used as the antibody.
- As an antigen, amyloid β (1-28) was used. Amyloid β (1-28) is present as a single molecule and an aggregate in a solution.
- Amyloid β (1-28) was trapped in the same manner as in (4) in Example 1 using the above-described affinity beads (6E10/4G8 F(ab′)-PEG24 beads, 6E10 F(ab′)-PEG24 beads, 4G8 F(ab′)-PEG24 beads, 6E10/4G8 IgG-protein G beads, 6E10 IgG-protein G beads, and 4G8 IgG-protein G beads). Further, MALDI-TOF MS was performed using a mass spectrometer in the same manner as in (6) in Example 1 to determine detection limits. FIG. 10 shows the MALDI-TOF MS spectra of amyloid β (1-28) eluates obtained when the 6E10 IgG-protein G beads were used (
FIG. 10A ), the MALDI-TOF MS spectra of amyloid β (1-28) eluates obtained when the 4G8 IgG-protein G beads were used (FIG. 10B ), the MALDI-TOF MS spectra of amyloid β (1-28) eluates obtained when the 6E10/4G8 IgG-protein G beads were used (FIG. 10C ), the MALDI-TOF MS spectra of amyloid β (1-28) eluates obtained when the 6E10 F(ab′)-PEG24 beads were used (FIG. 10D ), the MALDI-TOF MS spectra of amyloid β (1-28) eluates obtained when the 4G8 F(ab′)-PEG24 beads were used (FIG. 10E ), the MALDI-TOF MS 10 spectra of amyloid β (1-28) eluates obtained when the 6E10/4G8 F(ab′)-PEG24 beads were used (FIG. 10F ), and the MALDI-TOF MS spectra of pure amyloid β (1-28) (directly) spotted onto a MALDI plate without being trapped by beads (FIG. 10G ). The detection limits (S/N≥3) of amyloid β (1-28) in all the cases are shown in Table 2. -
TABLE 2 Detection Limit (S/N ≥ 3) Directly IgG-protein G F(ab′)-PEG24 Spotting 6E10 25 pg 5 pg 25 pg (7.67 fmol) (1.53 fmol) (767 amol) 4G8 25 pg 25 pg (7.67 fmol) (7.67 fmol) 6E10/ 4G8 25 pg 2.5 pg (7.67 fmol) (767 amol) - When the three kinds of IgG-protein G beads (6E10/4G8 IgG-protein beads, 6E10 IgG-protein G beads, and 4G8 IgG-protein G beads) were used, the detection limit was 25 μg in all the cases. On the other hand, when the 6E10 F(ab′)-PEG24 beads were used, the detection limit was 5 μg. That is, sensitivity when the 6E10 F(ab′)-PEG24 beads were used was 5 times higher than that when the IgG-protein G beads of each kind were used. It is considered that this is because space is created between each of the beads and −F(ab′) by PEG insertion so that steric hindrance becomes less likely to occur and the binding strength of antigen-antibody reaction is enhanced.
- On the other hand, the detection limit when the 4G8 F(ab′)-PEG24 beads were used was 25 μg that was the same as that when the 4G8 IgG-protein G beads were used. There is a case where F(ab′) fragmentation of IgG reduces the binding strength between antigen and antibody, but it has been found that the effect of PEG insertion to enhance the binding strength between antigen and antibody can compensate for a reduction in the binding strength between antigen and antibody due to the fragmentation of IgG.
- When the 6E10/4G8 F(ab′)-PEG24 beads were used, the detection limit was 2.5 μg, which was equivalent level to the detection limit achieved by directly spotting amyloid β (1-28) onto a MALDI plate.
- Here, from a simple calculation of the binding strengths of 6E10 F(ab′) and 4G8 F(ab′), the detection limit when the 6E10/4G8 F(ab′)-PEG24 beads are used is estimated to be about 15 μg that is the average of the detection limit when the 6E10 F(ab′)-PEG24 beads were used (5 μg) and the detection limit when the 4G8 F(ab′)-PEG24 beads were used (25 μg). However, the detection limit when the 6E10/4G8 F(ab′)-PEG24 beads were used was 2.5 μg that was 1/6 of the estimated detection limit. It is considered that this is because that binding strength is enhanced by cooperative binding achieved by the two kinds of antibody fragments (6E10 F(ab′) and 4G8 F(ab′)), which recognize different epitopes to each other, on each of the beads. On the other hand, the S/N ratio when the 6E10/4G8 F(ab′)-PEG24 beads were used was lower than that when pure amyloid β (1-28) was analyzed, from which it is considered that the eluate contained minute quantities of impurities (low-molecular compounds, metal ions, etc.).
- In order to measure target biomolecules in a biological sample by a mass spectrometer, it is important to eliminate impurities by isolating and concentrating the target molecules. In this example, an experiment was performed to examine the ability of the F(ab′)-PEGn beads to eliminate impurities by isolating and concentrating an objective to be trapped. As a biological sample, human plasma was used.
- One milliliter of a sample was prepared by spiking 1 ng (307 fmol) of amyloid β (1-28) in plasma obtained by diluting 50 μL of human plasma 20-fold with TBS-1% OTG. Amyloid β (1-28) in the sample was isolated and concentrated in the same manner as in (4) in Example 1. However, in this example, washing with TBS-1% OTG performed in Example 1 three times after the reaction between the beads and the sample was performed 5 times to eliminate impurities non-specifically adsorbed to the beads.
- For a reference experiment, amyloid β (1-28) was isolated and concentrated using the 6E10 F(ab′)-PEG24 beads, and was then analyzed by a mass spectrometer in the same manner as in (6) in Example 1. The thus obtained mass spectrum is shown in
FIG. 11(A) . As shown inFIG. 11(A) , many peaks other than the peak of amyloid β (1-28) were detected. - It is known that human anti-mouse antibody (HAMA) is present in human blood. Since 6E10 and 4G8 are mouse-derived IgGs, molecules of such an antibody bind thereto. In order to prevent such binding, before the plasma sample in which amyloid β (1-28) was spiked and the beads were mixed, human anti-mouse antibody contained in the plasma was removed by mixing the plasma sample and 50 μL of protein G agarose and incubating the mixture at 4° C. for 30 minutes. Then, mass spectrometry was performed in the same manner. The thus obtained mass spectrum is shown in
FIG. 11(B) . As shown inFIG. 11(B) , the many peaks other than the peak of amyloid β (1-28) were removed by removing human anti-mouse antibody. On the other hand, a high background spectrum was observed. - PEG has the property of incorporating positively-charged metal ions around negatively-charged oxygen atoms thereof. When being incorporated into PEG and then released from PEG by elution with HCl, metal ions contained in the reaction buffer and the plasma have an influence on analysis performed by the mass spectrometer. It is considered that this influence causes a high background in the mass spectrum. For this reason, 1 μL of a 2% aqueous methanediphosphonic acid (MDPNA) solution having the effect of reducing the background due to metal ions was mixed as a comatrix on the MALDI plate, and then mass spectrometry was performed. The thus obtained mass spectrum is shown in
FIG. 11(C) . As shown inFIG. 11(C) , a spectrum having a high S/N ratio was obtained. It is to be noted that the concentration of CHCA at which the best signal was obtained when 2% MDPNA was used in combination therewith was 5 mg/mL. - Under the above conditions, amyloid β (1-28) spiked in plasma was isolated and concentrated using the F(ab′)-PEG24 beads and analyzed by the mass spectrometer to determine the detection limit of amyloid β (1-28).
FIG. 12 shows the MALDI-TOF MS spectra of amyloid β (1-28) eluates obtained when the 6E10 IgG-protein G beads were used (FIG. 12A ), the MALDI-TOF MS spectra of amyloid β (1-28) eluates obtained when the 4G8 IgG-protein G beads were used (FIG. 12B ), the MALDI-TOF MS spectra of amyloid β (1-28) eluates obtained when the 6E10/4G8 IgG-protein G beads were used (FIG. 12C ), the MALDI-TOF MS spectra of amyloid β (1-28) eluates obtained when the 6E10 F(ab′)-PEG24 beads were used (FIG. 12D ), the MALDI-TOF MS spectra of amyloid β (1-28) eluates obtained when the 4G8 F(ab′)-PEG24 beads were used (FIG. 12E ), the MALDI-TOF MS spectra of amyloid β (1-28) eluates obtained when the 6E10/4G8 F(ab′)-PEG24 beads were used (FIG. 12F ), and the MALDI-TOF MS spectra of pure amyloid β (1-28) (directly) spotted on a MALDI plate without being trapped by beads (FIG. 12G ). The detection limits (S/N≥3) of amyloid β (1-28) in all the cases are shown in Table 3. -
TABLE 3 Detection Limit (S/N ≥ 3) Directly IgG-proteinG F(ab′)-PEG24 Spotting 6E10 50 pg 2.5 pg 1 pg (15.3 fmol) (767 amol) (307 amol) 4G8 25 pg 10 pg (7.67 fmol) (3.07 fmol) 6E10/ 4G8 5 pg 1 pg (1.53 fmol) (307 amol) - The detection limit when pure amyloid β (1-28) was detected by the mass spectrometer without being trapped by beads was 1 μg (307 amol) (
FIG. 12G ). The evaluation point of this example is to achieve a mass spectrometric detection level close to 1 μg (307 amol) by isolating and concentrating amyloid β (1-28) in plasma using the F(ab′)-PEG24 beads. It is to be noted that a detection limit of 1 μg (307 amol) achieved in this example is lower than that achieved in Example 2 using only the matrix CHCA. This is because the combined use of the matrix and the comatrix MDPNA reduces the background, which increases the S/N ratio. - Amyloid β (1-28) spiked in plasma was isolated and concentrated using the three kinds of F(ab′)-PEG24 beads (6E10 F(ab′)-PEG24 beads, 4G8 F(ab′)-PEG24 beads, and 6E10/4G8 F(ab′)-PEG24 beads) and the three kinds of IgG-protein G beads (6E10-protein G beads, 4G8-protein G beads, and 6E10/4G8-protein G beads). As a result, the lowest level of amyloid β (1-28) (1 μg) could be detected when the 6E10/4G8 F(ab′)-PEG24 beads were used. The detection level achieved in this case was equivalent to that when pure amyloid β (1-28) was analyzed by the mass spectrometer. However, also in this example, the S/N ratio when the 6E10/4G8 F(ab′)-PEG24 beads were used was lower than that when pure amyloid β (1-28) was analyzed, from which it is considered that the eluate contained minute quantities of impurities.
- Also among the three kinds of IgG-protein G beads, there was a difference in detection limit. Among them, the lowest level of amyloid β (1-28) (5 μg) could be detected when the 6E10/4G8 IgG-protein G beads were used. On the other hand, in Example 2, there was no difference in detection limit among the three kinds of IgG-protein G beads, but it was confirmed that the S/N ratio was highest when the 6E10/4G8 IgG-protein G beads were used. In Example 3, the probable reason why a low level of amyloid β (1-28) could be detected when the 6E10/4G8 IgG-protein G beads were used is that also when the protein G beads to which the two kinds of antibodies were bound were used, cooperative binding was achieved by the F(ab′) fragments of the different antibodies.
- In fact, the Non-Patent Document 2 (Proceedings of the Japan Academy, Ser. B, Physical and biological Sciences 2011; 87(9):603-16) states that the KD value of the amyloid β (1-15)-Fc6 antibody-like molecule in which PEG is not inserted into the hinge region is lower than that of amyloid β (1-15) peptide, that is, the amyloid β (1-15)-Fc6 antibody-like molecule in which PEG is not inserted into the hinge region is less likely to cause dissociation of anti-amyloid β antibody than amyloid β (1-15) peptide. The
Non-Patent Document 2 suggests that cooperative binding can be achieved also when the hinge region of the antibody-like molecule is the original hinge region of IgG (to which no PEG is inserted). This is suggested also by the result of SPR analysis. - In addition, the
Non-Patent Document 2 also states that the KD value of the antibody-like molecule having a hinge region into which PEG is inserted is lower than that of the antibody-like molecule having a hinge region into which PEG is not inserted. The tendency that the KD value is lowered by PEG insertion is seen also in the result of this example that the amount of the trapped antigen was larger when the 6E10/4G8 F(ab′)-PEG24 beads were used than when the 6E10/4G8 IgG-protein G beads were used. - Further, according to the result of SPR analysis in the
Non-Patent Document 2, the maximum binding amount (Rmax) of the amyloid β (1-15)-PEG24-Fc6 antibody-like molecule is 40 when the Rmax of the amyloid β (1-15)-Fc6 antibody-like molecule is 34.9. The tendency that the binding amount is increased by PEG insertion is also in accordance with the result of this example. - An experiment was performed to determine whether or not substances other than target amyloid β (1-28) were adsorbed to the beads.
FIG. 13 shows a mass spectrum obtained by analyzing, with a mass spectrometer, an eluate obtained by isolating and concentrating 1 μg (307 amol) of amyloid β (1-28) spiked in plasma using the 6E10/4G8 F(ab′)-PEG24 beads. As shown inFIG. 13 , when the 6E10/4G8 F(ab′)-PEG24 beads were used, no peaks (S/N≥3) other than the peak of amyloid β (1-28) were detected in the range of m/z 1,500 to 5,000. From the result, it is considered that non-specific adsorption of impurities was reduced by binding of highly-hydrophilic PEG to the beads and the absence of Fc regions of the antibodies. Therefore, it can be said that the F(ab′)-PEG24 beads are excellent also in specificity.
Claims (6)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/197,828 US20220017583A1 (en) | 2012-07-17 | 2021-03-10 | Affinity support and method for trapping substance using the same |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2012-158647 | 2012-07-17 | ||
JP2012158647A JP6231263B2 (en) | 2012-07-17 | 2012-07-17 | Affinity support and method of capturing a substance using the same |
PCT/US2013/043875 WO2014014563A1 (en) | 2012-07-17 | 2013-06-03 | Affinity support and method for trapping substance using the same |
US201514414329A | 2015-01-12 | 2015-01-12 | |
US17/197,828 US20220017583A1 (en) | 2012-07-17 | 2021-03-10 | Affinity support and method for trapping substance using the same |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/414,329 Continuation US10968263B2 (en) | 2012-07-17 | 2013-06-03 | Affinity support and method for trapping substance using the same |
PCT/US2013/043875 Continuation WO2014014563A1 (en) | 2012-07-17 | 2013-06-03 | Affinity support and method for trapping substance using the same |
Publications (1)
Publication Number | Publication Date |
---|---|
US20220017583A1 true US20220017583A1 (en) | 2022-01-20 |
Family
ID=49949164
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/414,329 Active US10968263B2 (en) | 2012-07-17 | 2013-06-03 | Affinity support and method for trapping substance using the same |
US14/600,498 Abandoned US20150177263A1 (en) | 2012-07-17 | 2015-01-20 | Affinity support and method for trapping substance using the same |
US17/197,828 Pending US20220017583A1 (en) | 2012-07-17 | 2021-03-10 | Affinity support and method for trapping substance using the same |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/414,329 Active US10968263B2 (en) | 2012-07-17 | 2013-06-03 | Affinity support and method for trapping substance using the same |
US14/600,498 Abandoned US20150177263A1 (en) | 2012-07-17 | 2015-01-20 | Affinity support and method for trapping substance using the same |
Country Status (12)
Country | Link |
---|---|
US (3) | US10968263B2 (en) |
EP (2) | EP3915659B1 (en) |
JP (2) | JP6231263B2 (en) |
CA (1) | CA2879097C (en) |
DK (2) | DK2874724T3 (en) |
ES (2) | ES2962141T3 (en) |
FI (1) | FI3915659T3 (en) |
HR (1) | HRP20210849T1 (en) |
LT (1) | LT2874724T (en) |
PT (2) | PT3915659T (en) |
SI (1) | SI2874724T1 (en) |
WO (1) | WO2014014563A1 (en) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6231263B2 (en) * | 2012-07-17 | 2017-11-15 | 株式会社島津製作所 | Affinity support and method of capturing a substance using the same |
PT3611180T (en) | 2013-03-15 | 2022-03-15 | Biomolecular Holdings Llc | Hybrid immunoglobulin containing non-peptidyl linkage |
JP6582995B2 (en) | 2014-01-21 | 2019-10-02 | 株式会社島津製作所 | Method for measuring APP-cleaved peptide |
PT3116486T (en) * | 2014-03-14 | 2020-03-12 | Biomolecular Holdings Llc | Hybrid immunoglobulin containing non-peptidyl linkage |
WO2016137398A1 (en) * | 2015-02-25 | 2016-09-01 | Agency for Science,Technology and Research | Device and method for detecting target molecules |
ES2734807T3 (en) | 2015-08-20 | 2019-12-12 | Hoffmann La Roche | Particle based immunoassay using a specific pegylated analyte binding agent |
CN108333361A (en) * | 2017-01-19 | 2018-07-27 | 深圳市新产业生物医学工程股份有限公司 | Bridging has magnetic microsphere compound formulation of antibody and the preparation method and application thereof |
ES2865511T3 (en) * | 2017-02-02 | 2021-10-15 | Hoffmann La Roche | Immunoassay using at least two pegylated analyte specific binding agents |
JP7156146B2 (en) * | 2019-04-10 | 2022-10-19 | 株式会社島津製作所 | Method for making hydrophilic material hydrophobic |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007050359A2 (en) * | 2005-10-21 | 2007-05-03 | Merck & Co., Inc. | Anti-addl monoclonal antibody and use thereof |
US20070157325A1 (en) * | 2005-12-30 | 2007-07-05 | Shahriar Mojtahedian | Process for identification of novel disease biomarkers in mouse models of alzheimer's disease including triple transgenic mice and products thereby |
WO2009015696A1 (en) * | 2007-08-02 | 2009-02-05 | Araclon Biotech | High sensitivty immunoassays and kits for the determination of peptides and proteins of biological interest |
US20090252731A1 (en) * | 2003-07-01 | 2009-10-08 | Immunomedics, Inc. | Multivalent Carriers of Bi-Specific Antibodies |
US10968263B2 (en) * | 2012-07-17 | 2021-04-06 | Biomolecular Holdings Llc | Affinity support and method for trapping substance using the same |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5217492A (en) * | 1982-09-29 | 1993-06-08 | Bio-Metric Systems, Inc. | Biomolecule attachment to hydrophobic surfaces |
JP2826965B2 (en) | 1995-01-12 | 1998-11-18 | オリエンタル酵母工業株式会社 | Immunoadsorbent and its production method |
SI1482987T1 (en) * | 2002-03-01 | 2014-12-31 | Bracco Suisse Sa | Multivalent constructs for therapeutic and diagnostic applications |
US7261876B2 (en) * | 2002-03-01 | 2007-08-28 | Bracco International Bv | Multivalent constructs for therapeutic and diagnostic applications |
GB0211805D0 (en) | 2002-05-22 | 2002-07-03 | Prometic Biosciences Ltd | Endotoxin-binding ligands and their use |
SE526038C2 (en) * | 2002-07-08 | 2005-06-21 | Gambro Lundia Ab | Polymer affinity matrix, process for its preparation and use thereof |
JP2006506447A (en) * | 2002-10-25 | 2006-02-23 | センス プロテオミック リミテッド | Proteins encoded by the BLE gene and novel methods for using bleomycin family-derived antibiotics |
EP1480041A1 (en) * | 2003-05-22 | 2004-11-24 | Innogenetics N.V. | Method for the prediction, diagnosis and differential diagnosis of Alzheimer's disease |
WO2005037881A1 (en) | 2003-10-17 | 2005-04-28 | Reverse Proteomics Research Institute Co., Ltd. | Affinity resin |
WO2005064327A1 (en) * | 2003-12-25 | 2005-07-14 | National Institute Of Advanced Industrial Science And Technology | Sugar chain structure profiling technique |
WO2005119258A1 (en) * | 2004-06-03 | 2005-12-15 | Kimio Katsuta | Method of simultaneously assaying plural number of substances and assay device to be used therein |
JP2008045906A (en) * | 2006-08-11 | 2008-02-28 | Chiba Univ | Affinity beads and manufacturing method thereof |
ES2537564T3 (en) * | 2006-11-01 | 2015-06-09 | Beckman Coulter, Inc. | Bonding surfaces for affinity testing |
EP2078040B1 (en) | 2006-11-02 | 2017-06-28 | Daniel J. Capon | Methods of producing hybrid polypeptides with moving parts |
EP2088426B1 (en) | 2006-11-29 | 2013-05-15 | Shimadzu Corporation | Mass spectrometry of biological sample using immunoprecipitation |
LT2842967T (en) * | 2007-01-18 | 2017-02-27 | Eli Lilly And Company | Pegylated amyloid beta fab |
WO2009064424A1 (en) | 2007-11-13 | 2009-05-22 | Rational Affinity Devices, L.L.C. | Tunable affinity ligands for the separation and detection of target substances |
JP5435878B2 (en) * | 2008-02-12 | 2014-03-05 | 富士フイルム株式会社 | Labeled particles with fragmented antibody immobilized on labeling substance |
GB0808908D0 (en) | 2008-05-16 | 2008-06-25 | Avecia Biolog Ltd | Purification process |
JP2013510297A (en) * | 2009-11-04 | 2013-03-21 | ノバルティス アーゲー | Positively charged species as a binding reagent in the separation of protein aggregates from monomers |
CA2817448C (en) * | 2010-12-23 | 2019-01-22 | F. Hoffmann-La Roche Ag | Binding agent |
WO2012177775A1 (en) | 2011-06-20 | 2012-12-27 | Akrivis Technologies, Llc | Reagents and methods for bispecific antibody-based binding of target molecules |
EP2784080B1 (en) | 2011-10-31 | 2019-12-18 | Shimadzu Corporation | Peptide-hinge-free flexible antibody-like molecule |
PT3611180T (en) | 2013-03-15 | 2022-03-15 | Biomolecular Holdings Llc | Hybrid immunoglobulin containing non-peptidyl linkage |
PT3116486T (en) | 2014-03-14 | 2020-03-12 | Biomolecular Holdings Llc | Hybrid immunoglobulin containing non-peptidyl linkage |
-
2012
- 2012-07-17 JP JP2012158647A patent/JP6231263B2/en active Active
-
2013
- 2013-06-03 EP EP21166848.8A patent/EP3915659B1/en active Active
- 2013-06-03 DK DK13820377.3T patent/DK2874724T3/en active
- 2013-06-03 SI SI201331892T patent/SI2874724T1/en unknown
- 2013-06-03 EP EP13820377.3A patent/EP2874724B8/en active Active
- 2013-06-03 JP JP2015523081A patent/JP2015529322A/en active Pending
- 2013-06-03 PT PT211668488T patent/PT3915659T/en unknown
- 2013-06-03 ES ES21166848T patent/ES2962141T3/en active Active
- 2013-06-03 WO PCT/US2013/043875 patent/WO2014014563A1/en active Application Filing
- 2013-06-03 FI FIEP21166848.8T patent/FI3915659T3/en active
- 2013-06-03 ES ES13820377T patent/ES2870536T3/en active Active
- 2013-06-03 PT PT138203773T patent/PT2874724T/en unknown
- 2013-06-03 US US14/414,329 patent/US10968263B2/en active Active
- 2013-06-03 DK DK21166848.8T patent/DK3915659T3/en active
- 2013-06-03 LT LTEP13820377.3T patent/LT2874724T/en unknown
- 2013-06-03 CA CA2879097A patent/CA2879097C/en active Active
-
2015
- 2015-01-20 US US14/600,498 patent/US20150177263A1/en not_active Abandoned
-
2021
- 2021-03-10 US US17/197,828 patent/US20220017583A1/en active Pending
- 2021-05-27 HR HRP20210849TT patent/HRP20210849T1/en unknown
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090252731A1 (en) * | 2003-07-01 | 2009-10-08 | Immunomedics, Inc. | Multivalent Carriers of Bi-Specific Antibodies |
WO2007050359A2 (en) * | 2005-10-21 | 2007-05-03 | Merck & Co., Inc. | Anti-addl monoclonal antibody and use thereof |
US20070157325A1 (en) * | 2005-12-30 | 2007-07-05 | Shahriar Mojtahedian | Process for identification of novel disease biomarkers in mouse models of alzheimer's disease including triple transgenic mice and products thereby |
WO2009015696A1 (en) * | 2007-08-02 | 2009-02-05 | Araclon Biotech | High sensitivty immunoassays and kits for the determination of peptides and proteins of biological interest |
US10968263B2 (en) * | 2012-07-17 | 2021-04-06 | Biomolecular Holdings Llc | Affinity support and method for trapping substance using the same |
Non-Patent Citations (4)
Title |
---|
Capon et al. ("Flexible antibodies with nonprotein hinges", Proc. Jap. Acad., Ser. B 87, 2011) (Year: 2011) * |
Peluso et al. (Analytical Biochemistry, vol. 312, pp. 113-124, published 2003) (Year: 2003) * |
Sun et al. ("Prediction of reversible disulfide based on features from local structural signatures", BMC Genomics (2017), vol. 18:279, pp. 1-10). (Year: 2017) * |
Thermo Fisher (<https://www.thermofisher.com/order/catalog/product/22114#:~:text=Thermo%20Scientific%20Pierce%20SM(PEG,to%2024%20ethylene%20glycol%20units>, retrieved on 12/12/2022) (Year: 2022) * |
Also Published As
Publication number | Publication date |
---|---|
JP2014020872A (en) | 2014-02-03 |
EP2874724A1 (en) | 2015-05-27 |
PT2874724T (en) | 2021-05-21 |
ES2962141T3 (en) | 2024-03-15 |
CA2879097A1 (en) | 2014-01-23 |
LT2874724T (en) | 2021-06-25 |
EP2874724B1 (en) | 2021-04-07 |
SI2874724T1 (en) | 2021-08-31 |
US20150197549A1 (en) | 2015-07-16 |
EP3915659A1 (en) | 2021-12-01 |
EP2874724A4 (en) | 2016-04-06 |
EP3915659B1 (en) | 2023-08-02 |
DK3915659T3 (en) | 2023-11-06 |
JP2015529322A (en) | 2015-10-05 |
WO2014014563A1 (en) | 2014-01-23 |
ES2870536T3 (en) | 2021-10-27 |
US10968263B2 (en) | 2021-04-06 |
JP6231263B2 (en) | 2017-11-15 |
FI3915659T3 (en) | 2023-11-03 |
EP2874724B8 (en) | 2021-05-12 |
US20150177263A1 (en) | 2015-06-25 |
CA2879097C (en) | 2022-07-19 |
PT3915659T (en) | 2023-11-10 |
DK2874724T3 (en) | 2021-05-25 |
HRP20210849T1 (en) | 2021-07-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20220017583A1 (en) | Affinity support and method for trapping substance using the same | |
JP6424757B2 (en) | Method for mass spectrometry of polypeptide | |
JP6582995B2 (en) | Method for measuring APP-cleaved peptide | |
US20230406880A1 (en) | Detection and quantification of glycosylated peptides | |
KR20210116502A (en) | Methods and systems for identifying and quantifying antibody fragmentation | |
CN117396758A (en) | Method for analyzing neuropeptide related to protein | |
KR20140137353A (en) | Selector based recognition and quantification system and method for multiple analytes in a single analysis | |
JP6891222B2 (en) | Affinity support and method of capturing substances using it | |
JP7298855B2 (en) | Affinity support and substance capture method using same | |
JP6542842B2 (en) | Affinity support and method for capturing substance using the same | |
WO2022270126A1 (en) | Method for analyzing antibody | |
CN114026109A (en) | Monoclonal antibody to amyloid beta, and method for measuring amyloid beta-related peptide using same | |
US20240053357A1 (en) | Analysis method | |
US20070148721A1 (en) | Compositions, methods, systems, and kits for affinity purification | |
EA047458B1 (en) | DETECTION AND QUANTIFICATION OF GLYCOSYLATED PEPTIDES |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: BIOMOLECULAR HOLDINGS LLC, CALIFORNIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:CAPON, DANIEL J.;REEL/FRAME:055562/0391 Effective date: 20200131 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |